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One of the major obstacles in varicella-zoster virus (VZV) research has been 
the lack of an efficient genetic system. To overcome this problem, we generated a full-
length, infectious bacterial artificial chromosome (BAC) system of the P-Oka strain 
(pP-Oka), which facilitates generation of mutant viruses and allowed light to be shed 
on the role in VZV replication of the ORF9 gene product, a major tegument protein, 
and ORFS/L (ORF0), a gene with no known function and no direct orthologue in other 
alphaherpesviruses. Mutation of the ORF9 start codon in pP-Oka, abrogated pORF9 
expression and severely impaired virus replication. Delivery of ORF9 in trans via 
baculovirus-mediated gene transfer partially restored virus replication of ORF9 
deficient viruses, confirming that ORF9 function is essential for VZV replication in 
vitro. Next we targeted ORFS/L and could prove that the ORFS/L gene product is 
important for efficient VZV replication in vitro. Furthermore, we identified a 5’ region 
of ORFS/L that is essential for replication and plays a role in cleavage and packaging 
of viral DNA. 
To elucidate the mechanisms of Marek’s disease virus (MDV) integration and 
tumorigenesis, we investigated two sequence elements of the MDV genome:  vTR, a 
virus encoded telomerase RNA, and telomeric repeats present at the termini of the 
virus genome. We demonstrate that vTR serves two distinct functions in MDV-
induced tumor formation. The first is dependent on an increase of telomerase activity 
 mediated by vTR, which contributes to the survival of rapidly dividing transformed 
cells and is crucial for rapid onset of lymphoma formation in infected animals. The 
second function of vTR is independent of telomerase action and is required for tumor 
formation and metastasis. This function is likely mediated by vTR interaction with 
RPL22, a cellular factor involved in T-cell development and virus-induced 
transformation. Finally, our studies on herpesvirus telomeric repeats provide the first 
conclusive evidence that herpesvirus telomeric repeats mediate integration into host 
telomeres, are critical for efficient tumor formation, and support efficient reactivation 
of latent virus. 
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CHAPTER ONE 
 
 
Introduction and literature review 
2 
1.1.  Herpesviridae 
The Herpesviridae family within the newly established order Herpesvirales is 
classified in three subfamilies, Alphaherpesvirinae, Betaherpesvirinae and 
Gammaherpesvirinae, based on their biological properties such as clinical 
manifestation, host range, preferential establishment of latency in certain cell types, 
and, more recently, genome structure and sequence (17, 84). Herpesviruses are 
abundant in nature, with one or frequently several distinct viruses found in most 
animal species. So far, more than 200 herpesviruses have been discovered and the 
number is steadily increasing (81). To date, eight human herpesviruses (HHV) have 
been identified. Among those are representatives from each subfamily, the 
Alphaherpesvirinae represented by herpes simplex virus 1 (HSV-1; HHV-1) herpes 
simplex virus 2 (HSV-2; HHV-2) and Varicella-zoster virus (VZV; HHV-3), the 
Betaherpesvirinae with human cytomegalovirus (HCMV; HHV-5), human herpesvirus 
6 (HHV-6) and 7 (HHV-7), and the Gammaherpesvirinae with Epstein-Barr virus 
(EBV; HHV-3) and Kaposi’s sarcoma-associated herpesvirus (KHSV; HHV-8). 
Herpesviruses contain a large linear, non-segmented, double stranded DNA. 
Genome sizes of herpesvirus species vary from 124 to 230 kbp in length. Based on the 
presence of direct and inverted repeats within their genome, herpesviruses are 
categorized into six genome classes, designated by the letters A through F. They 
encode between 60 and more than 230 genes that are mainly transcribed by host cell 
polymerase II and the cell’s transcription apparatus (81). In mature virions, the linear, 
non-segmented genome is encased in an icosahedral capsid that consists of 162 
capsomers and is 120 nm in diameter. The capsid is surrounded by a proteinaceous 
matrix termed tegument and then by an envelope composed of a large number of 
glycoproteins embedded in a lipid bilayer (Fig. 1.1). The size of the herpes virion 
3 
varies from approximately 150 nm to as much as 260 nm, which is partially dependent 
on the thickness of the tegument (81).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Schematic representation of the herpesvirus virion. The linear, double 
stranded DNA (dsDNA) genome in enclosed in an icosahedral nucleocapsid, which is 
surrounded by the tegument, a proteinaceous matrix, and the lipid envelope containing 
several viral glycoproteins. Modified from “Field’s Virology”(81). 
 
1.2. Alphaherpesvirinae 
The alphaherpesvirus subfamily, which diverged from the beta- and 
gammaherpesvirus lineages about 180-220 million years ago, contains numerous 
mammalian and avian viruses (64). Generally, members of the Alphaherpesvirinae are 
biologically characterized by relatively short replication cycles, a variable host range 
in vitro and the ability to establish latency in sensory neurons. Alphaherpesviruses are 
further classified in four genera. Members of the genus Simplexvirus and 
Varicellovirus harbor viruses that infect mammalian hosts, while members of the 
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Mardivirus and Iltovirus genus infect avian species(81). Human VZV and Marek’s 
disease virus (MDV) are two members of the Alphaherpesvirinae that will be 
discussed further in this dissertation.  
 
1.3. Alphaherpesvirus life cycle 
Alphaherpesvirus infection is initiated by the attachment of the virion to the 
host cell. This process is mediated by viral glycoproteins that are able to bind receptor 
molecules on the surface of the host cell (Fig. 1.2). The contact initiates fusion of the 
viral envelope with the plasma membrane, which results in the release of the 
nucleocapsid as well as tegument components into the cytosol (28, 40). Once in the 
cytosol, the capsid binds to microtubule-associated motors and is transported to the 
nucleus, where it docks to a nuclear pore through which the viral genome is released 
into the nucleus. Tegument proteins, such as VP16, are translocated into the nucleus, 
where they interact with the cellular transcription machinery and stimulate the 
expression of immediate early proteins (α proteins). Immediate early proteins are 
subsequently transported into the nucleus were they induce the transcription and 
expression of early (β) genes (43). Several β proteins are also translocated into the 
nucleus, where they facilitate the replication of the viral genome. Genome replication 
is initiated at the viral origins of replication and leads to the synthesis of concatemeric 
DNA likely through a rolling circle replication mechanism. During the replication 
process, transcription of late genes (γ proteins) is initiated. Late proteins are mainly 
involved in the process of assembly and/or are structural proteins of the virion (43). 
Components of the nucleocapsid are transported into the nucleus where capsid 
assembly occurs (66). Packaging sites, pac1 and pac2, within concatemeric DNA are 
recognized by the viral cleavage and packaging machinery, whereupon replicated 
DNA is cleaved into unit length genomes and packaged into preformed nucleocapsids 
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(65). DNA-containing viral capsids associate with several tegument proteins and bud 
through the nuclear envelope into the cytoplasm, where additional tegumentation 
occurs. Subsequently, capsids are transported to the trans-Golgi network, in which 
they bud into and obtain their final envelope (66). After budding into those vesicles, 
mature virions are transported to the plasma membrane where they are released via 
fusion of the vesicle with the plasma membrane. In addition, virions can be 
specifically redirected to cell junctions that results in spread of infectivity to 
neighboring cells by a not fully understood mechanism (46). Some herpesviruses, such 
as VZV and MDV, almost exclusively utilize cell-to-cell transfer of virus for viral 
spread in vitro and in vivo, while cell free VZV and MDV virions are only produced in 
differentiated epithelial cells of hair and feather follicles, respectively (80). 
 
1.4. Herpesvirus latency 
Latency is one of the most intriguing features of the herpesvirus life cycle. It 
ensures the maintenance of the viral genome in the host for extended periods of time 
in the absence of productive lytic replication. This latent state can be maintained 
throughout the life of the host allowing continued persistence, while sporadic 
reactivation events ensure the dissemination to naïve individuals. Establishment of 
latency is cell-type dependent and can occur in several lymphoid and neuronal cells. 
Members of the Alphaherpesvirinae subfamily predominantly establish latency in 
sensory neurons of the peripheral nervous system (48). One exception is Marek’s 
disease virus (MDV) which maintains latency exclusively in the peripheral blood 
mononuclear compartment (PBMC) compartment, predominantly in infected CD4+ T-
cells (10, 94).  
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Figure 1.2. Model of the alphaherpesvirus replication cycle. The first step of the 
herpesvirus life cycle is the attachment to the target cell, which is mediated by viral 
glycoproteins. Subsequently, the viral envelope fuses with the plasma membrane, 
which results in the release of the capsid into the cytosol. The capsid is transported to 
the nucleus, where it docks to a nuclear pore and releases the linear viral genome into 
the nucleus. In the nucleus, a cascade of viral transcripts is initiated, with immediate 
early genes (α proteins) at first, then early (β proteins) and late genes (γ proteins). β 
proteins provide the components for DNA replication, while γ proteins contribute 
structural components. Rolling circle replication of the viral genome results in 
concatemeric viral DNA, which is cleaved into unit length genomes and packaged into 
preformed capsids. DNA-containing capsids bud through the nuclear membrane and 
are released into the cytosol, where they obtains most tegument components. 
Subsequently, capsids bud into the Golgi compartment and thereby obtain their final 
envelope. The mature virus particles bud into vesicles that transport the virions to the 
plasma membrane where they are released by exocytosis. Modified from Mettenleiter 
et al. 2002 (66) 
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The virus genome can have three different states in the host nucleus: i) As an 
episome as observed in the case of HSV-1 and VZV; ii) tethered to host chromosomes 
as was shown for EBV (90), and iii) integrated into the host genome, which represents 
a unique mechanism utilized by some herpesviruses and which is discussed in detail in 
CHAPTER 5.  
 
1.5. Varicella-zoster virus 
Varicella-zoster virus (VZV), a highly cell-associated alphaherpesvirus, also 
known as human herpesvirus 3 (HHV-3), is one of the eight known human 
herpesviruses. It belongs to the genus Varicellovirus, which includes several 
mammalian viruses such as pseudorabies virus (PRV), equine herpesvirus 1 (EHV-1), 
bovine herpesvirus 1 (BoHV-1), and the closest relative of VZV, simian varicella 
virus (SVV) (17). Primary infection with VZV usually occurs early in life and results 
in varicella, also known as chicken pox, which is associated with fever and a 
generalized rash. During primary infection VZV is able to infect neurons of sensory 
ganglia, where it establishes latency. Reactivation of VZV from the latent state results 
in the development of herpes zoster, also known as shingles, in the form of a localized, 
mostly very painful vesicular rash that can lead to postherpetic neuralgia (13). VZV is 
highly transmissible via airborne vesicular droplet infection and direct contact (35, 
86). In contrast to HSV that is labile under dry conditions (99), dehydrated VZV is 
stable in the environment for at least 2 years at various temperatures (27, 58), ensuring 
efficient transmission and persistence of the virus in the population.  
In recent years, novel VZV research tools have light on molecular mechanisms 
involved in VZV pathogenesis. First, the development of an animal model for VZV, a 
severe combined immunodeficiency (SCID) mouse model with human tissue 
xenografts, with histopathology comparable to the disease in humans, allowed new 
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insights in VZV pathogenesis in vivo (55, 70). Secondly, a genetic system for VZV, 
consisting of four overlapping cosmids harboring the entire VZV genome, was 
developed. This cosmid-based approach allowed the generation of VZV mutants in 
E.coli, while virus could be reconstituted by cotransfection of all four cosmids into 
cells susceptible to VZV infection (14, 75). The only drawback of the system is that 
reconstitution of the virus is dependent on the recombination of cosmids in 
mammalian cells, which can result in genetic rearrangements and has low efficiency. 
To overcome this obstacle, we generated a bacterial artificial chromosome (BAC) 
system, as described in CHAPTER 2.  
 
1.6. Varicella-zoster virus genome structure 
The VZV genome, the smallest among the human herpesviruses, is 
approximately 125 kbp in size and encodes at least 70 unique open reading frames 
(ORFs) (2). The organization of the VZV genome is similar to that of HSV-1 and over 
90% of the VZV ORFs have counterparts (orthologues) in the HSV-1 genome (2, 49). 
As has been reported for all alphaherpesviruses, the VZV genome consists of two 
unique regions, the unique long (UL) and unique short (US) segment, each flanked by 
inverted repeat regions (TRL, IRL, TRS, IRS) (Fig. 1.3) (18). In contrast to HSV-1, the 
prototype alphaherpesvirus, VZV contains only very short repeats (88 bp) on either 
end of the UL(16). During alphaherpesvirus replication, four isomers of viral DNA are 
generated, which can be distinguished by the orientation of UL and US relative to each 
other. While all four possible isomers of HSV-1 DNA are represented in the virion in 
equimolar amounts, virions produced by VZV and other members of the genus 
Varicellovirus, such as EHV-1, predominantly contain only two isomeric forms of the 
genome (16, 26, 36, 54, 96). Southern blot analysis of VZV virion DNA demonstrated 
that inversion of the UL region is rare amounting to only approximately 5% (16) and 
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could also be attributed to a rare circular configuration of the genome within the virion 
(50). A previous report on EHV-1 suggested that inversion of the UL region in infected 
cells is common, but that packaging occurs in a directional manner (96). For both 
VZV and EHV-1, the reason for the preferential orientation of the UL has remained 
unknown and will be further discussed in CHAPTER 3.  
 
 
 
 
 
 
 
Figure 1.3. VZV and MDV genomes. Schematic representation of the VZV (upper 
panel) and MDV (middle panel) genome. The two unique regions unique long (UL) 
and short (US) as well as the terminal (TRL, TRS) and internal (IRL, IRS) inverted 
repeat regions are shown. A focus on the a-like sequences in MDV is shown including 
the multiple telomeric repeats (mTMR), short telomeric repeats (sTMR), cleavage and 
packaging sites pac1 and pac2 as well as DR1 sites (lower panel). The number of 
isomers in VZV and MDV virions is shown.  
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1.7. Varicella-zoster virus pathogenesis  
Primary VZV infection is initiated by the inhalation of aerosolized droplets 
from, or by direct contact with, individuals with ongoing varicella or reactivated 
herpes zoster (Fig. 1.4) (35, 86, 87). In the upper respiratory tract, VZV is thought to 
infect epithelial cells of the oronasal mucosa and is subsequently able to spread to the 
regional lymphoid tissue (Waldeyer’s ring) and lymph nodes where it gains access to 
highly permissive CD4+ T-cells. The entry of infected T-cells into the bloodstream 
causes a primary viremia within four to six days of initial infection, which allows the 
virus to spread to several organs including liver and spleen. VZV then replicates in 
these organs resulting in a secondary viremia (28). During the incubation period, 
infected T-cells transport the virus to replication sites in the skin. VZV replication in 
epidermal cells results in the vesicular rash referred to as chickenpox. Aerosolization 
of vesicular fluid or direct contact with naïve individual allows the further 
dissemination of the virus. During primary infection, VZV is able to establish latency 
in cranial nerves as well as dorsal root and autonomic ganglia, where it remains 
dormant until a reactivation event occurs (30). In the latent state, the majority of the 
viral genome is transcriptionally silent and no infectious virus is produced. 
Reactivation of VZV occurs primarily in the elderly or immunocompromised 
individuals and results in the development of shingles (herpes zoster), which is often 
associated with severe pain and postherpetic neuralgia (2). 
 
1.8. Marek’s disease virus 
MDV, also known as gallid herpesvirus type 2 (GaHV-2), belongs to the genus 
Mardivirus. Besides MDV, two related but distinct species belong to the same genus, 
GaHV-3 (previously referred to as MDV-2) and turkey herpes virus 1 (HVT), also 
known as meleagrid herpesvirus type 1 (MeHV-1) (8).
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Figure 1.4. Model of VZV pathogenesis. VZV infection is initiated by the inhalation 
of cell free VZV. In the upper respiratory tract, VZV is able to infect epithelia cells 
and subsequently reaches primary lymph nodes. In a primary viremia, VZV spreads to 
liver, spleen and other organs where the virus replicates. In a secondary viremia, VZV 
reaches the skin, which results in the typical rash as well as establishment of latency in 
neurons of the sensory ganglia. VZV is able to reactivate from the latently infected 
neurons, which results in a localized vesicular rash. Modified from “Principles of 
virology”(28). 
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Marek’s disease was named after József Marek who first described the disease 
as a general polyneuritis in adult animals in 1907 (62). Since then, the clinical picture 
of the disease has changed dramatically. At first it was described as a sporadic and 
chronic condition. However over the years the disease developed into an aggressive 
and acute form, which can cause more than 90% morbidity and mortality in 
susceptible animal populations (80, 91). The first cases of visceral lymphomas in 
conjunction with the prevalent neurological symptoms were reported in the mid 1950s. 
In addition, strains that developed over the past 25 years also cause severe brain 
edema and acute death even in fully vaccinated animals (80, 101). The virulence of 
different MDV strains can be classified into mildly virulent (m), virulent (v), very 
virulent (vv) and very virulent plus (vv+) (102). A number of MDV strains have been 
cloned as bacterial artificial chromosomes (BAC), which allow manipulation of the 
viral genome as well as their maintenance in E. coli (82, 83, 89).  
  
1.9. Marek’s disease virus genome structure 
 The 180-kbp linear, double-stranded DNA genome of MDV consists of two 
unique sequences (UL and US) flanked by terminal (TRL or TRS) and internal (IRL or 
IRS) inverted repeats (Fig. 1.3) (95). MDV also contains a-like sequences, which are 
present in an identical orientation at both ends of the linear genome as well as in an 
inverted orientation at the IR L-S junction. Upon circularization, one terminal copy of 
the a-like sequence is deleted (76). The a-like sequences of MDV have been found to 
contain a stretch of multiple telomeric repeats (mTMR) of variable lengths flanked by 
the cleavage and packaging signals pac1 and pac2 adjacent to the direct repeat 1 
(DR1) (52). In addition, a shorter stretch of telomeric repeats (sTMR) invariably 
consisting of six TMRs has been identified upstream of the PacI site (Fig. 1.3). Unit 
length genomes are generated by cleavage of viral concatemeric DNA within DR1, 
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and are subsequently packaged into preformed capsids within the nucleus (5). Both 
packaging sites as well as DR1 are required for efficient cleavage and packaging. 
Whether the TMRs are also required for MDV in these processes has not been shown. 
However, Dewhurst and colleagues demonstrated that TMRs in HHV-6 are 
dispensable for virus cleavage and packaging using a plasmid-based approach (23).  
 
1.10. Marek’s disease virus pathogenesis 
 The initial infection of the chicken occurs via the respiratory route upon 
inhalation of infectious, cell-free MDV from a contaminated environment (Fig. 1.5). 
In the respiratory tract, MDV is able to infect macrophages or dendritic cells (DCs) 
(9). Infection of these cell types can be facilitated by an initial round of replication in 
epithelial cells. MDV subsequently uses infected macrophages and DCs as “transport 
vehicles” to lymphoid organs such as the spleen, thymus and bursa of Fabricius where 
the virus is detected within 24 hours after initial infection (88). Resident B-cells and 
later CD4 T-cells in these organs serve as a primary target for the first phase of 
cytolytic replication. Between days 3 and 6 post infection (dpi), the productive 
cytolytic replication provokes acute inflammation, which leads to an influx of 
macrophages, B-cells and T-cells. At 7 to 8 dpi, cytolytic infection in lymphoid organs 
changes and MDV enters the latent phase (9).  Latency largely remains restricted to 
CD4+ T-cells and rarely occurs in B-cells or CD8+ T-cells (94). Infected CD4+ T-
cells not only play an essential role in latency and transformation, but are also crucial 
for virus spread within the infected animal. Using infected CD4+ T-cells as a 
“shuttle”, MDV is able to enter feather follicle epithelia, where infectious virus is 
produced and shed into the environment in a cell-free state (47, 80). In addition, MDV 
also gets transported into several non-lymphoid organs such as liver, lung, kidney, 
esophagus, proventriculus, intestine and adrenal glands, which serve as sites for the 
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second phase of cytolytic infection (9). However, MDV is not only able to stay latent 
in infected lymphocytes and travel throughout an animal, but is also able to transform 
infected cells, which ultimately leads to cellular immortalization and lymphoma 
formation in multiple organs.  
 
 
 
 
Figure 1.5. Model of MDV pathogenesis in chickens. Infection is initiated by the 
inhalation of cell free MDV. Macrophages are thought to transfer the virus to regional 
lymph nodes spleen, thymus and bursa, where the virus replicates in B cells and 
subsequently in T-cells. MDV is able to establish latency in infected T-cells, which 
transported the virus to the skin and feather follicle epithelia (FFE), where cell free 
MDV is generated. MDV is also able to transform T-cells, which often results in 
tumor formation. Obtained from Jarosinski et al. (45). 
 
 
1.11. Herpesvirus genome integration and tumorigenesis 
 A number of DNA viruses and retroviruses are capable of integrating into the 
host genome, ensuring viral genome maintenance and replication during cell division. 
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Several herpesviruses integrate into the host genome, for example EBV, HHV-6, 
HHV-7 and MDV, whereas others maintain their genome in an episomal state. 
Delecluse and coworkers demonstrated that MDV integrates predominantly at the 
distal ends of host chromosomes (22). Strikingly, HHV-6 has also been found to 
integrate into telomeric regions at the very ends of the chromosomes (61, 72). This 
indicates that telomeres, which are important for chromosome maintenance via 
telomerase and an alternative elongation mechanism (ALT) (74), may play a role in 
the integration and latency of certain herpesviruses. As mentioned above, the MDV 
genome also contains repeats of telomeric sequences (TTAGGG) at both ends of the 
genome as well as within the internal repeat region (Fig 1.3). Besides MDV, other 
herpesviruses from all three classes contain these sequences at the very end of their 
genome. Among those are viruses closely related to MDV, GaHV-3 and HVT, the β-
herpesviruses HHV-6 and HHV-7 as well as the γ-herpesvirus equine herpesvirus type 
2 (EHV-2). Intriguingly, viruses that harbor telomeric repeats (TMRs) establish 
latency in lymphocytes, which requires faithful replication of the viral genome during 
proliferation of the latently infected host cells (44). The role of the telomeric 
sequences within the viral genome is not known at present. Several functions are 
possible, for example i) integration into the host genome via homologuous 
recombination, ii) recognition of the genome as a mini chromosome by the cell, iii) 
and/or they play a role in the cleavage and packaging of viral DNA.  
 
1.12. Telomere structure and function 
Telomeres are specialized structures located at the distal end of eukaryotic 
chromosomes (Fig. 1.6A). This DNA-protein complex is thought to fulfill at least five 
vital functions. Firstly, telomeres protect chromosome ends from terminal degradation 
by exonucleases (98), which would lead to successive loss of genetic information. 
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Secondly, they prevent illegitimate recombination mediated by the cellular 
recombination machinery in the presence of free double strand DNA ends (20, 63). 
Thirdly, telomeres inhibit the activation of DNA damage responses, which recognize 
genomic double-strand breaks and induce apoptosis in case of severe damage to the 
genome (98). Fourthly, cytogenetic studies indicate that telomeres are located at the 
nuclear periphery, suggesting that telomeres might be involved in the chromosomal 
organization within the nucleus (1). Finally, telomeres including its proteinaceous 
moieties provide a solution for the end replication problem, which arises from the 
inability of the replication machinery to amplify the terminal sequences of the lagging 
strand (100).  
In eukaryotes, telomere DNA usually consists of tandem repeats, 5-8 bp in 
length with a high guanine (G) content (60). In vertebrates, the telomeric repeat 
sequence is highly conserved and is comprised of the hexanucleotide repeat 
(TTAGGG)n. Telomeric repeats are protected by a protein complex termed shelterin. 
Three shelterin proteins, telomere recognition factor 1 and 2 (TRF-1 and TRF-2) and 
POT1, interact directly with the telomeric repeats (19). Other proteins, such as TIN2, 
TPP1 and Rap1, interconnect the individual components and facilitate shelterin 
complex formation (67). At the telomere ends, the G rich strand extends past the 
complementary strand as a 3′ overhang, which is stabilized by POTI and forms a T 
loop by invasion into the double-stranded telomeric DNA (42).  
Telomere length varies greatly among species and lengths ranging from 20 bp 
in some ciliated protozoan species such as Oxytricha (53), a few hundred bp in S. 
cerevisia e(85), 4-14 kbp  in humans (20), 10-150 kbp in mice (51) and 10-2000 kbp 
in chickens (21). 
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Figure 1.6. Telomeres and Telomerase. A) Schematic representation of a eukaryotic 
chromosome. Telomeres are shown at both ends and telomeric repeat sequences 
(TTAGGG)n are indicated. B) Telomerase-mediated telomere extension. The 
telomerase complex, including telomerase reverse transcriptase (TERT, light blue) and 
telomerase RNA (TR), bind to the shortened telomere (upper panel) and adds several 
repeats to the telomere end (middle panel). The complementary strand is subsequently 
synthesized by the DNA polymerase. Modified from 
stemcells.nih.gov/info/scireport/appendixC.asp. 
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1.13. Telomere maintenance and telomerase 
Replication of chromosome ends poses an intriguing problem, due to the 
inability of the DNA polymerase to fully replicate the 3′ end of the lagging strand. 
Watson and Olovnikov independently recognized this phenomenon and hypothesized 
that the chromosome termini would be progressively shortened with every cell 
division (78, 79, 100). Indeed, chromosome shortening was observed in proliferating 
cells in vitro corroborating the hypothesis of Watson and Olovnikov (20, 37). In 
addition, telomere length decreases with age of an individual (38, 59), confirming that 
telomere shortening also occurs in vivo. Furthermore, somatic human cells are limited 
in the number of cell divisions, suggesting chromosome shortening acts as a molecular 
clock regulating the replicative potential of cells (39). Continuous cell proliferation 
occurs until telomeres reach a critical limit which triggers an irreversible growth arrest 
called cellular senescence (93). Excessive shortening also greatly increases the 
incidence of end-to-end fusion of chromosomes and the activation of DNA damage 
responses which can result in the induction of apoptosis (31, 97). 
Telomerase, a multi-component ribonucleoprotein complex, counteracts this 
gradual telomere loss by adding telomeric repeats onto chromosome ends (Fig. 1.6B). 
The telomerase complex, which was first discovered in the ciliate Tetrahymena (33), 
consists of two main components, telomerase reverse transcriptase (TERT) and 
telomerase RNA (TR), as well as many associated proteins. As the catalytic subunit of 
the complex, TERT facilitates the reverse transcriptase reaction, which results in the 
addition of telomeric repeats to chromosome termini, while TR provides the RNA 
template for the reaction. Counterparts of TERT have been identified in various 
organisms including ciliates, yeast, mammalian and avian species. The size of TERT 
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varies from 103 kDa in S. cerevisiae, 127 kDa in humans and mice, 134 kDa in 
Tetrahymena to 155 kDa in chickens (11, 15, 32, 73). All TERT family members 
contain seven conserved reverse transcriptase (RT) motifs that are located in a central 
region of the protein (3). TERT harbors two independent RNA binding domains.  The 
first, a high-affinity binding domain is comprised of three conserved telomerase 
specific motifs that bind a conserved region (CR4-CR5) of human TR (56, 68). A 
second, low-affinity binding domain is though to interact with human TR within the 
pseudoknot-template domain (71). 
TR contains four structural domains, which are highly conserved regions (CR) 
in all vertebrates: i) the pseudoknot (core) domain, containing the template sequence 
(CR1); ii) the H/ACA box and iii) the conserved region (CR) 7 domain, both of which 
are essential for TR stability and localization; and iv) the CR4-CR5 domain, which is 
required for efficient TR-TERT complex formation, hence telomerase activity and 
processivity (12, 29).  Besides TERT and TR, several other proteins also directly 
interact with the telomerase complex in humans, such as the chaperone p23, hStau, 
ribosomal protein L22 (RPL22) and dyskerin, which are thought to regulate 
telomerase assembly, modification, localization and enzymatic activity (3, 57, 69, 77). 
However, TERT and TR alone are sufficient to reconstitute the holoenzyme and to 
exhibit telomerase activity (34). 
While TR is highly expressed in most cell types, TERT expression is limited to 
only a subset of cell types and is therefore the limiting factor for telomerase activity. 
Germ-line and stem cells exhibit high telomerase activity that is sufficient to maintain 
a constant telomere length, allowing the indefinite proliferation of such cells. 
However, most somatic cells do not exhibit telomerase activity, limiting the number of 
replication cycles of differentiated cells (92). Expression of telomerase components in 
somatic cells in trans is sufficient to prevent telomere loss and to promote 
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immortalization and continued proliferation and growth (4). Furthermore, telomerase 
activity is highly upregulated in more than 90% of human cancers (92), underlining 
the role of telomere maintenance in tumor development. Inhibition of telomerase 
activity in immortalized human cells results in telomere shortening and cell death (41), 
making the system an intriguing target for cancer therapy (24). Some tumors and cells 
derived thereof, however, are able to maintain their telomeres in the absence of any 
detectable telomerase activity by an alternative lengthening of telomeres (ALT) 
pathway (6, 7). The ALT process relies on homologous recombination between 
telomeres, which will result in the copying of telomere sequences (25). Still, the 
telomerase complex is the key player in telomere elongation. With its cell type-
specific activity, it allows an efficient maintenance of telomeres in germ-line and stem 
cells, while somatic cells only have a limited proliferative capability, which is thought 
to keep potential cancer progenitor cells in check. 
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A Self-Excisable Infectious Bacterial Artificial Chromosome Clone of 
Varicella-Zoster Virus Allows Analysis of the Essential Tegument Protein 
Encoded by ORF9  
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2.1. Abstract 
In order to facilitate mutant virus generation in varicella zoster virus (VZV), the 
agent causing varicella (chickenpox) and herpes zoster (shingles), we generated a full-
length infectious bacterial artificial chromosome (BAC) clone of the P-Oka strain.  
First, mini-F sequences were inserted into a preexisting VZV cosmid, and the 
SuperCos replicon was removed.  Subsequently, mini-F containing recombinant virus 
was generated from overlapping cosmid clones, and full-length VZV DNA recovered 
from the recombinant virus was established in Escherichia coli as an infectious BAC.  
An inverted duplication of VZV genomic sequences within the mini-F replicon 
resulted in markerless excision of vector sequences upon virus reconstitution in 
eukaryotic cells.  Using the novel tool, the role of the major tegument protein encoded 
by ORF9 for VZV replication was investigated.  A markerless point mutation 
introduced in the start codon by two-step en passant Red mutagenesis abrogated 
ORF9 expression and resulted in a dramatic growth defect that was not observed in a 
revertant virus.  The essential nature of ORF9 for VZV replication was ultimately 
confirmed by restoration of growth of the ORF9-deficient mutant virus using trans-
complementation via baculovirus mediated gene transfer. 
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2.2. Introduction 
Varicella-zoster virus (VZV), the causative agent of chickenpox (varicella) and 
shingles (herpes zoster), is a highly cell-associated herpesvirus both in vitro and in 
vivo (7, 23).  Similar to the situation in a closely related alphaherpesvirus, Marek’s 
disease virus (MDV), VZV spreads directly from cell to cell, presumably utilizing the 
machinery involved in adherens junction modeling and architecture. Infectious virus is 
only released into the environment after lytic VZV replication in the skin and 
respiratory mucous membranes of infected individuals (2, 43).  Efficient and timely 
coordinated interaction between the tegument, a proteinaceous structure surrounding 
the icosahedral nucleocapsid, and envelope membrane (glyco)proteins plays a crucial 
role in secondary envelopment and spread of herpesviruses in general and VZV in 
particular (34).  It has been shown for related viruses such as herpes simplex virus 
(HSV) that the inner layer of tegument is tightly associated with the nucleocapsid, 
whereas the outer layer of tegument provides the link to envelope proteins (35, 36).  
The current model of herpesviral tegumentation predicts that the inner layer of 
tegument is added to the nucleocapsid in the nucleus and de-enveloped particles in the 
cytoplasm, while proteins representing the outer layer are thought to accumulate at 
cytoplasmic membranes where they make contact with their respective partners, either 
other tegument proteins and/or membrane proteins (34-36).  Through these intricately 
regulated interactions, final secondary envelopment of particles is facilitated and, 
ultimately, infectious virus is produced and released.   
Determination of the role of individual tegument or membrane (glyco)proteins in 
the replication cycle of various herpesviruses is not trivial, because, in vitro, many of 
the functions appear redundant (34, 35).  Analyses of viral mutants have shown, 
however, that similar sets of structural proteins are required for most 
alphaherpesviruses.  VZV and MDV seem to be the exceptions to the rule.  Not only 
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do they share important biological properties with respect to growth in vitro and in 
vivo, they also exhibit striking similarities with respect to the membrane 
(glyco)proteins as well as tegument proteins that they absolutely require for 
replication.  For example, both glycoproteins E and I (gE and gI), which form a 
noncovalently linked complex in infected cells and virions, are essential for growth of 
both viruses, at least in certain cell types, while they are dispensable in all other 
alphaherpesviruses tested (3, 8, 25, 37, 42, 50, 63, 65).  In contrast, the major viral 
transactivator encoded by VZV ORF10 (MDV UL48) is dispensable for growth of 
either virus, but is essential for most related viruses (17, 19, 20, 58, 61).  In this 
context it must be noted that the MDV UL49 product, the ORF9 homologue of VZV, 
was shown to be absolutely required for growth of the chicken virus.  The facts that 
this tegument protein was shown to physically interact with gE in the case of related 
herpesviruses and that gE is essential for both VZV and MDV (4, 21, 29, 30, 38, 50) 
prompted us to investigate the role of the ORF9 product in the VZV life cycle. 
Since mutagenesis of herpesviruses using standard techniques that are based on 
homologous recombination in cultured cells by default results in a steady positive 
selection for viral replication, manipulation of genes that are crucial for viral 
replication in non-complementing cells is virtually impossible. In addition, 
propagation in cultured cells increases the risk of introducing compensatory mutations 
within the viral genome. Generation of stable trans-complementing cell culture 
systems for virus mutagenesis is not always possible because herpesviral genes are 
expressed at a defined stage of viral replication, at a certain level, and can even be 
toxic if expressed in the absence of other viral proteins. These drawbacks of 
conventional mutagenesis are even more dominant in the case of slowly replicating, 
highly cell-associated viruses, making it virtually impossible to transfer virus from 
trans-complementing to non-complementing cells.  As the first step out of this 
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predicament, herpesviral genomes were cloned as overlapping cosmid clones in E. 
coli, which makes all the bacterial methods for sequence modification available, but is 
also prone to selective pressure, at least at the sites of recombination of the individual 
cosmids during virus reconstitution (15, 48, 57, 59).  In the case of a replication-
deficient virus reconstituted from cosmid clone, it is virtually impossible to 
discriminate between failure of cosmid recombination, a lack of trans-
complementation, the essential nature of the manipulated sequence or any unwanted 
fatal second site mutations within viral sequences.  As an improvement over cosmid 
cloning and a logical next step, a number of herpesviral genomes, including the VZV 
genome, were previously cloned as bacterial artificial chromosomes (BAC).  Full-
length viral DNA sequences can be maintained in E. coli, manipulated with targeted or 
random techniques, and finally mutant viruses are derived right after transfection of 
permissive cells (1, 5, 14, 32, 33, 40, 47, 49, 52, 53).   
Herpesviral genomes range from approximately 100 to 300 kb in size and are 
densely packed with open reading frames totaling ~70 to ~220 genes.  They also 
contain direct and indirect repeat sequences and sequence duplications (10, 31, 60).  
Having such optimized genomes also means that overlapping regulatory sequences are 
found within open reading frames, along with polycistronic transcription units, 
expression of multiple splice variants, anti-sense RNAs, and miRNA’s (11, 12, 22, 26, 
45, 46).  To avoid collateral and spurious effects of herpesvirus mutagenesis, the need 
for minimal sequence modifications emerges.  Such techniques, in addition to the 
desirable removal of previously introduced mini-F sequences that are necessary for 
maintenance in bacteria, should result in markerless modification or at least in 
modifications that will only result in the introduction of very small sequences, such as 
frt or loxP sites (59).   
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We here report on the generation of an infectious clone of the intensively 
characterized and fully sequenced VZV strain P-Oka, which served as the starting 
point for the generation of the widely used V-Oka vaccine strain (54).  The infectious 
BAC was generated utilizing previously generated cosmid clones that were modified 
using Red recombination technique (39, 41, 64).  A recently developed method that 
allows markerless modification of cloned DNA in E. coli was used to introduce a 
sequence duplication into the mini-F vector, which results in removal of all vector 
sequences upon virus reconstitution in eukaryotic cells (55).  Finally mutants were 
generated that were unable to express the major tegument protein encoded by ORF9, 
which were unable to replicate unless the protein was provided in trans, indicating that 
this major regulatory and structural tegument protein is essential for VZV replication. 
 
2.3. Material and Methods 
Viruses and Cells.  Wild-type P-Oka and mutant viruses were propagated and 
passaged in human melanoma cells (MeWo) grown Dulbecco’s minimal essential 
medium (DMEM) or in minimal essential medium (MEM) containing, 10% fetal 
bovine serum (FCS) and a mixture of penicillin and streptomycin (Invitrogen).  Virus 
was passaged and amplified by cocultivation of infected with uninfected cell at a ratio 
of 1/2 to 1/5.  Virus stocks were frozen down in growth media supplemented with 8% 
DMSO and stored in liquid nitrogen. 
Construction of transfer vectors.  For construction of the mini-F transfer vector, 
plasmid pUC18 was PCR amplified with primers (5’-CTT CTA GAC ACG TGT TCG 
CTA CCT TAG GAC CGT TAT AGT TAC GAG TAA TCA TGG TCA TAG CTG 
TTT C-3’ and 5’-TGT CTA GAA GCC GGC ACT CGA GCA CGT GTT CGC TAC 
CTT AGG ACC GTT ATA GTT ACG TCA CTG GCC GTC GTT TTA C-3’), 
cleaved with XbaI and re-ligated to derive pCeu2.  The 2.6 kb SalI fragment of the 
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rightmost cosmid, pSpe23 (41), was ligated into the XbaI site of pCeu2.  The entire 
construct was amplified via inverse PCR using primers (5’-AGA GCT AGC GGA 
TAA AAG CGT ACT GTT TTT TAT T-3’ and 5’-AGA GCT AGC CGG TGT ATG 
TTT TAA ATT TAT T-3’) inserting an NheI restriction site between the polyA sites 
of ORF64 and ORF65.  The resulting plasmid was termed pCeu2.6Nhe (Fig. 2.1A).  
To introduce a NheI site into the mini-F vector pBeloBAC11 (New England 
Biolabs) and to remove its cos and loxP sequences, the mini-F plasmid was cleaved 
with SalI and the 6.4 kb fragment was ligated with the XhoI-treated oligo-homodimer 
of primer 5’-AGC CTC GAG CTA GCT CGA GGC TA-3’.  The derived plasmid, 
pBeloNhe, was cleaved with NheI and cloned into the NheI site of pCeu2.6Nhe, 
resulting in recombinant plasmid pBelo-P-Oka-in (Fig. 2.1A). 
The pEP-P-Oka-DX-in transfer vector for insertion of duplicated sequences into 
the mini-F plasmid was generated as follows.  First, a 1.7 kb BglII-ScaI-fragment was 
cloned via BamHI/SmaI into pCUCeu (56).  The segment flanked by NruI and EcoRI 
was replaced by a PCR product (5’-TAC GGA ATT CCG GAT GAG CAT TC-3’ and 
5’-CCC GGG ATC CTG CAG TCG ACA CGT GGC GCG CCT AGG TAT AAA 
TAC CTG TGA CGG AAG ATC AC-3’) of the equivalent sequence extended with a 
multiple cloning site (MCS). Then, an aphAI-I-SceI PCR product derived from 
pEPkan-S using primers (5’-GGC GCG CCG GCC AGT GTT ACA ACC AAT TAA 
CC-3’; 5’-TCG CGA TAA GCT CAT GGA GCG GCG TAA CCG TCG CAC AGG 
AAG GAC AGA GAT AGG GAT AAC AGG GTA ATC GAT TT-3’), which 
included a short duplication of pBeloBAC11 sequences, was inserted into a singular 
NruI site (55), ultimately resulting in the universal transfer vector pEPMCS-in-Belo 
(Fig. 2.1C).  A 1.6 kb PCR fragment of P-Oka (Primer: 5’-ACT AGT GCT TCT GCG 
CAC AAT GCC ACA G-3’ and 5’-ACT AGT GAA CGG TAC TTC GCC GCC GCG 
C-3’) was cloned into BlnI of the MCS to derive pEP-P-Oka-DX-in (Fig. 2.2). 
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Figure 2.1.  Schematic of vector construction.  A)  pBelo-P-Oka-in.  In a first step, 
recombinant plasmid pCeu2 was constructed by inverse PCR and self-ligation of 
pUC18 modifying the multiple cloning site (MCS).  The 2.6 kb SalI fragment of P-
Oka was cloned into the engineered XbaI site.  Another inverse PCR/ligation step was 
used to insert an NheI site close to the border of IRS and US sequences.  The mini-F 
replicon, pBeloNhe, was linearized and cloned into the newly inserted NheI site.  B)  
pSpe23-Belo.  The mini-F replicon with adjoining flanks A and B was released from 
plasmid pBelo-P-Oka-in by cleavage with I-CeuI and inserted into pSpe23 via Red 
recombination (55). Subsequently, SuperCos sequences were removed by AscI digest 
and self-ligation.  C)  pEPMCS-in-Belo.  The 1.7 kb BglII/ScaI fragment of 
pBeloBAC11 was cloned into pCUCeu (56).  A small portion of the pBelo sequence 
was replaced by a PCR product to introduce a multiple cloning site (MCS).  A PCR 
was performed to add NaeI and NruI sites and a small sequence duplication 
(arrowheads) to the aphAI-I-SceI cassette.  Cloning of that fragment into the NruI site 
of the MCS resulted in the en passant-ready transfer vector pEPMCS-in-Belo. The 
pBelo flanks used for Red recombination with pBelo-derived BACs are indicated with 
striped bars.   
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Figure 2.1 (continued) 
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Figure 2.2.  Insertion and self-excision of mini-F replicon.  Schematic of the insertion 
of pBelo sequences between ORF64 and ORF65 (lines 1 to 3).  A 1.6 kb sequence of 
P-Oka was inserted between the bacterial origin of replication (OriS) and cat to create 
an inverse duplication of VZV sequences adjoining the mini-F replicon. The orange-
red gradient bar indicates such duplicate sequences and their orientation.  Dotted lines 
indicate recombination events of identical sequences (same colored bars) for a first 
Red recombination and of short duplications (red arrow) for the removal of the 
kanamycin resistance gene aphAI.  The BAC with duplicated sequences was termed 
pP-Oka-DX and maintained in E. coli under steady chloramphenicol selection.  Upon 
transfection of MeWo cells, two anti-parallel recombination events (orange and red 
dotted lines) released mini-F sequences and resulted in rP-Oka-F¯.  Primers P1 (5’-
TTA ACT CAG TTT CAA TAC GGT GCA G-3’) and P2 (5’-TGG GGT TTC TTC 
TCA GGC TAT C-3’) were used to screen for presence of mini-F sequences, as well 
as P3 (5’-AGG CAT TTC AGT CAG TTG CTC-3’) and P4 (5’-TGC CAC TCA TCG 
CAG TAC TG-3’) for the presence of cat.  The loss of the pBelo insert was detected 
utilizing primers P5 (5’-ATT GGA AGC GAC GTC GAC AC-3’) and P6 (5’-TGT 
AAC GCG CGT AAT ACA GAT CG-3’).  
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Red recombination.  Red recombination was performed exactly as described 
earlier using E. coli strain EL250 harboring the respective cosmid or BAC DNA (27, 
55).  All primers used for mutagenesis were PAGE purified (Integrated DNA 
Technologies, IDT). To perform en passant mutagenesis, a linear DNA fragment 
(PCR products using pEPkan-S as a template or a linearized plasmids) was used to 
introduce a cassette of aphAI, an I-SceI site and a short sequence duplication into the 
target sequence in a first step.  The resulting intermediates were selected with 30 
µg/ml kanamycin and 30 µg/ml  chloramphenicol on agar plates.  An I-SceI 
expressing plasmid (pBAD-I-sceI) was then introduced into EL250 harboring desired 
co-integrates, the expression of the homing endonuclease was induced with 0.5% 
arabinose, and a second Red recombination was performed. The loss of the aphAI-I-
SceI cassette was detected via replica plating, RFLP analysis and the identity of the 
introduced mutations was confirmed by nucleotide sequencing (55). 
Reconstitution of recombinant VZV from cosmid DNA.  Recombinant pP-
Oka-derived VZV was reconstituted by transfecting human melonama (MeWo) cells 
with pSpe23-Belo and the three other cosmid clones pFsp73, pSpe14 and pPme2 using 
the CalPhos Mammalian Transfection Kit (Clontech) exactly as previously described 
(14, 41). 
Generation of ORF9 mutants by en passant mutagenesis.  Primers 5’-TTT 
GGA TAT TTC ACG ACC CTA TCG TTT ATT TAC GTG CCG GCA TCT TCC 
GAC GGT GAT AGG GAT AAC AGG GTA ATC GAT TT-3’ and 5’-TTA GAG 
CGA CAA AGT CTG TCA CCG TCG GAA GAT GCC GGC ACG TAA ATA AAC 
GAT AGG CCA GTG TTA CAA CCA ATT AAC C-3’ were used to amplify the 
aphAI-I-SceI cassette present in pEPkan-S.  The pP-Oka9∆M mutants resulting from 
the en passant procedure were analyzed by RFLP and sequencing (data not shown). 
Using primers 5’-TGG ATA TTT CAC GAC CCT ATC GTT TAT TTA CGT AAT 
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GGC TAG CTC CGA CGG TGA CAT AGG GAT AAC AGG GTA ATC GAT TT-
3’ and 5’-TGC ATT AGA GCG ACA AAG TCT GTC ACC GTC GGA GCT AGC 
CAT TAC GTA AAT AAA CGG CCA GTG TTA CAC CAA TTA ACC-3’, a 
revertant clone from pP-Oka∆9M termed pP-Oka9Mr was generated by en passant 
mutagenesis as well.  The repaired ORF9 encoded for the wild-type amino acid 
sequence, but harbored a NheI site close to its start codon, which allowed unequivocal 
identification via RFLP (Fig. 2.5A). 
Reconstitution of VZV from BAC DNA.  BAC DNA for transfections was 
prepared using affinity chromatography following the manufacturer’s instructions 
(DNA Maxiprep system, Qiagen).  Subsequently, MeWo cells were transfected with 
Lipofectamin 2000 (Invitrogen).  Briefly, 1 to 4 µg BAC DNA were cotransfected 
with 200 ng pCMV62, a plasmid which contains the VZV IE gene ORF62 under the 
control of a CMV promoter (44).  The DNA lipofectamin solution was added onto the 
cells in 1 ml of MEM and incubated for 4 h.  Transfection medium was then replaced 
with MEM-10% FBS. 
Immunofluoescence.  Cells were fixed with 2% paraformaldehyde in PBS, 
permeabilized with 0.1% saponin, and blocked with 10% neonatal calf serum (NCS) 
in PBS. Primary antibodies, monoclonal anti-ORF62 antibody (Chemicon), 
monoclonal anti-gB antibody (US Biological), and ORF-9 polyclonal antibody (6) (a 
kind gift of Dr. William Ruyechan, SUNY Buffalo, NY), were each diluted 1:500 in 
PBS containing 10% NCS and 0.02% sodium azide.  Secondary antibodies, including 
Alexa 568-conjugated goat anti-rabbit and Alexa 488-conjugated goat anti-mouse 
antibodies, were diluted 1:1,000 in PBS.  Samples were examined under a 
fluorescence microscope and photographed with a digital camera (Zeiss Axiovert 25 
and Axiocam).   
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  Multi-step growth kinetics. Multi-step growth kinetics of P-Oka, rP-Oka, 
rP-Oka9∆M and rP-Oka9Mr derived viruses were determined by inoculating 1x106 
MeWo cells with 100 plaque-forming units (pfu) of cell-associated virus.  Infected 
cells were trypsinized on days 1, 2, 3, 4 and 5 and titrated by co-cultivation of 10-fold 
dilutions of trypsinized cells with fresh MeWo cells.  Five days after co-seeding, viral 
plaques were stained by indirect immunofluorescence using anti-gB antibodies (US 
Biological) and counted, exactly as described elsewhere (56).  All titer determinations 
were done in triplicate. 
Generation of recombinant baculoviruses expressing ORF9. A shuttle 
plasmid for the generation of recombinant baculoviruses by Tn7 transposition was 
generated as described earlier (9).  Briefly, the polyhedron promotor of the shuttle 
plasmid pFastBac1 (Invitrogen) was removed by digestion with SnaBI and HpaI and 
replaced with a 3.1 kb NruI-Bst1107I fragment from pcDNA3, which contains the 
HCMV-IE promoter/enhancer, the multiple cloning site and polyadenylation signal 
followed by the simian virus 40 (SV40) promoter-neomycin phosphotransferase II 
expression cassette. The resulting plasmid was named pFastM.  ORF9 was inserted 
into the multiple cloning site of pFastM using BamHI and XhoI restriction sites 
resulting in recombinant plasmid pFastMORF9. 
The expression cassette of pFastMORF9 was incorporated into the baculovirus 
genome by using Tn7 site-specific transposition according to the manufacturer's 
instructions for the Bac-to-BacTM expression system (Invitrogen).  Resulting bacmid 
DNA was purified and transfected into Sf9 cells using Cellfectin (Invitrogen).  After 
incubation at 27°C for 4 days, the resulting recombinant baculovirus, bMORF9, was 
propagated in Sf9 cells and viral titers were determined in a conventional plaque assay 
using neutral red agarose overlays (9).  One milliliter of bMORF9–containing 
supernatant was used for infection of MeWo cells seeded in 6-well-plates (25 
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pfu/cell).  Incubation was allowed for 30 min at RT, centrifuged for 5 min at 200 x g, 
and finally 10 mM butyrate was added to the cells to facilitate transgene expression 
(9).  After 4 h of incubation, cells were washed and 2 ml of DMEM-10% FBS was 
applied. 
 
2.4. Results  
Generation of an infectious P-Oka BAC clone.  The generation of the P-Oka 
BAC was based on overlapping cosmid clones that had been established earlier (41).  
Mini-F vector sequences were inserted into one of the P-Oka cosmids via Red 
recombination.  Briefly, the pSpe23 cosmid was electroporated into E. coli strain 
EL250 (27) and recombinant plasmid pBelo-P-Oka-in (Fig. 2.1B) was linearized with 
I-CeuI.  The 9.4 kbp fragment containing linear mini-F sequence and sequences 
flanking the junction between the VZV internal repeat short (IRS) and unique short 
(US) was electroporated into recombination-competent EL250 harboring pSpe23  (27, 
55).  Chloramphenicol resistant bacteria were selected and screened by restriction 
fragment length polymporphism (RFLP) analyses for correct insertion of the 
pBeloBac sequences into the rightmost P-Oka cosmid (data not shown). The derived 
construct, pSpe23-Belo-Cos, was cleaved with AscI to remove the SuperCos 
sequences and re-ligated resulting in pSpe23-Belo (Fig. 2.1B). The generated mini-F 
clone, which now was located within the rightmost P-Oka sequences, was transfected 
with the other overlapping cosmid clones to reconstitute a P-Oka virus mutant with the 
mini-F insertion. Total cellular and viral DNA isolated from MeWo cells infected with 
the P-Oka-BAC virus was cleaved with the enzymes AscI, which is unable to cleave 
P-Oka-BAC sequences, and λ exonuclease to digest cellular DNA. Remaining P-Oka-
BAC DNA (pP-Oka) was precipitated and electroporated into EL250 cells.  Bacteria 
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containing the full-length VZV genome were selected with chloramphenicol and 
screened by RFLP analysis (Fig. 2.3A).   
Reconstitution and characterization of recombinant pP-Oka-derived VZV.  
In order to demonstrate that the insertion the mini-F sequence in the VZV genome did 
not have a detrimental effect on viral replication in vitro, recombinant rP-Oka was 
reconstituted from the full-length infectious clone (pP-Oka) and growth kinetics were 
determined. Human melanoma cells (MeWo) were transfected with pP-Oka clones by 
lipofection.  Efficiency was increased by cotransfection with the pCMV62 plasmid 
(44).  Transfected cells were analyzed by immunofluorescence microscopy to detect 
plaque formation as early as 4 days post transfection. Multi-step growth kinetics 
revealed that BAC derived rP-Oka exhibited growth properties that were virtually 
identical to those of parental, wild-type P-Oka virus (Fig. 2.3B). Therefore, neither the 
increased size of the viral genome nor the insertion of the mini-F sequences into the 
chosen genomic locus had measurable effects on viral replication.   
Self-excision of mini-F sequences upon rP-Oka reconstitution.  Mini-F 
sequences of pP-Oka were removed employing a stabilized inverse sequence 
duplication.  The self-excision is based on the duplication within the mini-F of a VZV 
sequence that is present adjacent to the mini-F insertion site.  The duplication was 
introduced between the origin of replication and the antibiotic resistance gene (Fig. 
2.2) by first constructing an en passant-ready transfer construct, pEP-P-Oka-DX-in 
(43, 55) (Fig. 2.1C).  A 4.5 kb I-CeuI fragment was used to insert the 1.6 kb sequence 
duplication into mini-F sequences of pP-Oka via en passant mutagenesis in inverse 
orientation.  The resulting BAC, pP-Oka-DX, was maintained in E. coli by standard 
chloramphenicol selection.  The loss of vector sequences in E. coli through 
intramolecular recombination is prevented by the inverse orientation of the internal 
sequence duplication and its placement between the chloramphenicol resistance gene  
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Figure 2.3.  Confirmation of P-Oka BAC. A) Southern Blot of P-Oka, pP-Oka, pP-
Oka-DX, and rP-Oka-F⎯.  BAC DNA was prepared from E. coli harboring pP-Oka or 
pP-Oka-DX.  MeWo cells were infected with the parental virus P-Oka or with the 
recombinant rP-Oka-F¯, harvested at >80% of infection, and total DNA was prepared.  
BAC DNA (10 µg) or viral DNA (20 µg) was digested with BamHI or NcoI, separated 
on a 1% agarose gel, and transferred to a nylon membrane.  VZV BAC specific bands 
were detected using random DIG-labeled (DIG DNA labeling kit, Roche) sonicated 
pP-Oka DNA.  B) rP-Oka has growth kinetics that are very similar to those of wild- 
type P-Oka.  Multi-step growth kinetics of P-Oka and rP-Oka were performed using 
MeWo cells.  Means and standard deviations of three independent experiments are 
given. 
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cat and the mini-F origin OriS (data not shown).  Also, recombination of the 
duplication and identical sequences present in the terminal repeat short (TRS) would 
separate the resistance gene and the mini-F replicon, which would be lethal to the 
bacteria.  Consequently, pP-Oka-DX was stable in E. coli due to the constant selective 
pressure for plasmid replication and chloramphenicol resistance. 
After establishing stable maintenance of pP-Oka-DX in E. coli, MeWo cells were 
transfected with pP-Oka-DX.  Since there is no positive selection for maintenance of 
the mini-F replicon or chloramphenicol resistance in eukaryotic cells, intra- and 
intermolecular recombination leading to removal of the chlorampenicol resistance 
gene, the mini-F replicon, and the duplicated sequences can take place.  Reconstituted 
rP-Oka-F¯ virus reconstituted from the pP-Oka-DX BAC was passaged, harvested for 
DNA preparation, and the loss of the mini-F sequences was confirmed via PCR and 
sequencing (Fig. 2.2 and 2.4).  After the first passage of rP-Oka-F¯ the absence of the 
pBeloBAC cassette was observed in the majority of genomes, but a small fraction of 
viral genomes still harbored cat or the mini-F replicon until passage 4.  The rP-Oka-F¯ 
genome was also analyzed via Southern Blot analysis and its restriction enzyme 
pattern was indistinguishable from that of P-Oka DNA (Fig. 2.3A).   
Characterization of an ORF9 deficient VZV mutant.  To create a P-Oka 
mutant unable to express ORF9 protein, the start codon of the corresponding open 
reading frame (ORF9) was inactivated by markerless en passant mutagenesis (55).  A 
revertant was also generated in which the start codon was repaired and a NheI site was 
introduced to allow unequivocal identification of the revertant (Fig. 2.5A).  MeWo 
cells were transfected with pP-Oka DNA, DNA of the start codon mutant pP-Oka9∆M 
or the revertant pP-Oka9Mr to reconstitute the respective recombinant viruses (rP-
Oka, rP-Oka9∆M and rP-Oka9Mr).  Upon reconstitution, rP-Oka9∆M exhibited 
drastically decreased plaque sizes when compared to parental rP-Oka and the revertant  
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Figure 2.4.  PCR analysis of mini-F self excision upon transfection.  MeWo cells were 
transfected with pP-Oka-DX.  Reconstituted virus was passaged by mixing infected 
and uninfected cells at a ratio of 1 to 5.  DNA from virus passages was used to 
perform a PCR reaction with primers P1 and P2 (top panel) or P3 and P4 (middle 
panel) to detect remaining pBelo sequences in viruses reconstituted from pP-Oka-DX. 
Primers P5 and P6 were used to show the restoration of the P-Oka wild-type genomic 
organization in rP-Oka-F¯ (see also Fig. 2.2).  pP-Oka-DX DNA isolated from E. coli 
as well as total DNA of MeWo infected with P-Oka or uninfected MeWo cells were 
used as controls. Mini-F sequences are not detectable after 5 passages and in a 
significant portion of reconstituted virus the pBelo insert is lost right upon 
transfection. 
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Figure 2.5.  Growth properties of an ORF9-negative VZV.  A) Genomic region of 
VZV ORF9 with a focus on the aminoterminal sequence of ORF9 is shown.  The 
original nucleotide and amino acid sequences (black) are given, as are the mutations 
introduced in pP-Oka9∆M and its revertant (lines 2 and 3). B) Multi-step growth 
kinetics of rP-Oka, rP-Oka9∆M and rP-Oka9∆Mr.  Kinetics were performed in 
triplicate and means and standard deviations are given.   
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virus pP-Oka9Mr (Fig. 2.6A). IF analysis using ORF9-specific polyclonal antibodies 
revealed that, as expected, rP-Oka9∆M does not express ORF9 (Fig. 2.6A upper 
panel) (6).  On the other hand, ORF62 could readily be detected in the parental, the 
ORF9 deletion, and the revertant virus (Fig. 2.6A lower panel). In order to confirm the 
dramatic growth defect of rP-Oka9∆M, multi-step growth kinetics were performed.  In 
contrast to rP-Oka9∆M whose growth curve stayed flat, the rP-Oka9Mr revertant 
virus, in which the start codon of ORF9 had been repaired, grew with kinetics that 
were virtually indistinguishable from those of wild-type P-Oka and parental rP-Oka 
virus (Fig. 2.5B). Since rP-Oka9∆M showed no replication that would be sufficient for 
virus propagation leading to self excision of mini-F sequences, characterization of 
ORF9 was performed using recombinant viruses still harboring pBeloBAC sequences.   
To confirm that the impaired growth was only due to the lack of ORF9 
expression, we used baculovirus mediated gene delivery to complement growth of rP-
Oka∆9M. Baculoviruses have been shown to be an effective vehicle for introduction 
of DNA sequences into mammalian cells since they neither replicate nor cause 
cytopathic effects (24).  MeWo cells were transfected with pP-Oka∆9M DNA and 
infected at 1, 2, 3, 4 or 5 days post-transfection with a recombinant baculovirus 
expressing ORF9 under the control of the HCMV-IE promoter. After BAC 
transfection and baculovirus infection, cells were analyzed via immunofluorescence 
using anti-gB and anti-ORF9 antibodies at day 7 post transfection (6). The trans-
complementation via baculoviruses at days 1, 2 and 3 post transfection resulted in 
replication, and, consequently, significantly increased plaque sizes of rP-Oka∆9M 
(Fig. 2.6B).  
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Figure 2.6. Immunofluorescence analysis and trans-complementation via baculovirus 
mediated gene transfer. A) Plaque analysis of rP-Oka (left panels), rP-Oka9∆M 
(middle panels) and rP-Oka9Mr (right panels).  Plaques were analyzed by indirect 
immunofluorescence using anti-ORF9 polyclonal (6) and anti-ORF62 monoclonal 
antibodies (Chemicon, USA) at day 7 post transfection. B) Plaque analysis of rP-Oka 
(left panel), rP-Oka9∆M (middle panel) and rP-Oka9∆M rescued with baculovirus 
gene delivery at day 2 post transfection (right panel).  Plaques were analyzed via 
indirect immunofluorescence using anti-gB monoclonal antibody (US Scientific, 
USA) at day 7 post transfection.   
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2.5. Discussion 
In this study we demonstrated that the generation of a full-length bacterial 
artificial chromosome (BAC) directly from overlapping cosmid clones is possible. We 
could show that Red mutagenesis proved an efficient means to transfer a second 
bacterial origin of replication, here the mini-F replicon, into a pre-existing cosmid 
clone.  Having the BAC cassette within viral sequences ahead of virus reconstitution 
from the cosmids produces VZV BAC genomes without the need of (mostly 
inefficient) selection in cell culture.  Furthermore, removal of contaminating cellular 
chromosomal DNA from BAC DNA using restriction enzyme cleavage and λ 
exonuclease digestion before electroporation of the infectious VZV genome into E. 
coli was found to be more efficient than standard methods of DNA preparation (33, 
49). The strategy as described here, therefore, has the potential to be widely applicable 
for the cloning of herpesvirus genomes from already established cosmid clone 
systems, particularly with regard to highly cell-associated viruses.  
Whenever bacterial sequences are used to manipulate viral genomes, the overall 
effect of introduced, foreign sequence scars, like the mini-F cassette itself, for viral 
replication is not predictable.  The newly developed system applying an inversely 
oriented sequence duplication between the selection marker (antibiotic resistance 
gene) and the bacterial replicon allows stable maintainenance of the herpesviral 
genome in E. coli.  It also presents an in cis tool to remove the mini-F cassette upon 
transfection.  In the particular case described here, four passages in cultured cells were 
required to completely remove mini-F sequences from recombinant genomes as 
assayed by PCR.  The highly cell-associated nature and slow replication kinetics of 
VZV, which could account for polyclonal growth of VZV within the same infected 
cell, could be one possible explanation for the maintenance of a few mini-F containing 
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genomes in the first few cell culture passages. In addition, the lack of a growth 
advantage of recombinant virus devoid of mini-F sequences (rP-Oka-F¯) over viruses 
still carrying vector (rP-Oka-DX) could also contribute to the detection of mini-F 
sequences until passage 4.  Placing mini-F sequences within a gene that is essential for 
virus replication or using the developed methodology in faster replicating viruses 
producing cell-free infectivity would increase the efficiency of self excision of vector 
sequences (Wussow and Tischer, unpublished data). The combination of the VZV-
BAC clone at hand, the established techniques to perform markerless mutagenesis in 
E. coli, and the construction of a self-excisable BAC allows the creation of clonal 
virus progeny with minimal sequence modification.   
Similar to the situation in MDV, the generation of the full length P-Oka BAC 
clone, from the already established system of overlapping cosmid clones, allowed us 
to address genes that likely were crucial for VZV growth in cell culture. We were able 
to characterize the role of ORF9 in VZV replication.  Immunofluorescence analyses of 
rP-Oka∆9M with an ORF9 specific moloclonal antibody showed the lack of ORF9 
production in infected cells, which were, however, reactive with an anti-ORF62 
antibody. The repair of the ORF9 start codon restored ORF9 expression as well as 
virus growth in cell culture to levels observed with parental virus (Fig. 2.6A).  
Complementation via baculovirus-mediated gene delivery was also able to rescue 
productive viral replication. These results clearly demonstrated that ORF9 is essential 
for productive replication of VZV in cell culture, as is the case for MDV but unlike the 
situation in related human or animal alphaherpesviruses (13, 17, 18, 28). That supports 
the theory that highly cell-associated alphaherpesviruses mainly utilize the UL49-
gE/gI pathway to spread from cell to cell, whereas the loss of the UL49 homologue in 
herpesviruses that produce cell-free virions is less crucial for virus propagation. The 
characterization of UL49 negative mutants with less cell associated viruses allows the 
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analysis of other, nonstructural functions of that tegument protein as well (51, 62), 
while with VZV and MDV such a detailed characterization would required a very 
detailed dissection of respective functional domains. In addition, the highly cell-
associated nature of VZV makes it virtually impossible to work with phenotypically 
rescued mutant viruses because such viruses cannot be purified from trans-
complementing cells. 
Complementation of rP-Oka∆9M with the baculovirus expression system, 
however, was able to restore virus growth and significantly increase plaque sizes, 
albeit not to the level of wild-type or revertant viruses.  One explanation for the failure 
to completely restore VZV growth is that baculovirus mediated gene expression 
decreases with time; therefore, the amounts of ORF9 produced may not be sufficient 
at the end of the experiment.  Another reason might be that relatively low doses of 
recombinant baculovirus (MOI=25) were used, which resulted in the absence of ORF9 
expression in a subset of cells limiting the availability of ORF9 for replication of rP-
Oka∆9M.  Low MOI infection was chosen to prevent overexpression of ORF9, which 
had been shown to lead to cytotoxic effects and likely is one of the reasons for the 
failure to generate permanent cell lines (Kaufer, Tischer and Osterrieder, unpublished 
observations).  Another explanation might be that ORF9 expression is controlled by 
the strong HCMV-IE promoter. This promoter is constitutively active and transgene 
expression, therefore, cannot be modulated during the course of infection by virus-
encoded transcription factors as is the case during regular VZV infection. Constant, 
not synchronized, high-level expression of ORF9 may be detrimental to virus 
replication as has been suggested in the MDV system (16, 17). 
In summary, we have generated an infectious herpesvirus (VZV) BAC clone from 
overlapping pieces of cloned viral DNA. Advances of focused and minimal sequence 
modification in bacteria allowed characterization of the essential nature of ORF9 of 
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the highly cell associated herpesvirus VZV for in vitro replication. The established 
methodology is likely applicable to many other (herpes)viruses and has the advantage 
that the initial cloning step is independent of virus replication and that no selective 
pressure is applied because cosmid clones are usually derived from viral DNA 
packaged in nucleocapsids. Employing an inverse sequence duplication in the 
infectious BAC for cis-recombination allowed scarless self-excision of the mini-F 
replicon, which is not only important for the generation of viruses and mutants free of 
foreign sequences, but also represents an important step forward with respect to 
recombineering of viral sequences in eukaryotic cells. In addition, since cosmid and 
mini-F plasmid origins of replication can be maintained in the same bacterial cell as 
demonstrated here, successive assembly of a full-length viral mini-F clone from 
overlapping cosmid clones in bacteria applying Red recombination seems feasible and 
is currently being attempted. Viral genome assembly would avoid a eukaryotic stage 
in the generation of an infectious clone and be obtained without applying any positive 
or negative selection on the viral genomes.   
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3.1. Abstract  
The genome of varicella-zoster virus (VZV), a human alphaherpesvirus, consists 
of two unique regions, unique long (UL) and unique short (US), each of which is 
flanked by inverted repeats. During replication, four isomers of the viral DNA are 
generated, which are distinguished by the relative orientations of UL and US.  VZV 
virions predominantly package two isomeric forms of the genome that have a fixed 
orientation of the UL. ORFS/L, an open reading frame (ORF) with unknown function 
is located at the extreme terminus of UL, directly adjacent to the a-like sequences, 
which are known to be involved in cleavage and packaging of viral DNA. We 
demonstrate here that ORFS/L localizes to the Golgi network in infected and 
transfected cells. Furthermore, we were able to demonstrate that deletion of the 
complete ORFS/L gene is lethal, while retention of the N-terminal 28 amino acids 
resulted in viable virus. The growth defect was only partially attributable to the 
expression of the ORFS/L product, suggesting that the 5′ region of ORFS/L contains a 
sequence element crucial for cleavage/packaging of viral DNA.  Consequently, 
mutations introduced into the 5′ region of ORFS/L resulted in a defect in DNA 
cleavage, indicating that the region is indeed involved in processing of viral DNA. 
Since the sequence element has no counterpart on the opposite end of UL, our results 
provide an explanation for the almost exclusive orientation of the UL seen in packaged 
VZV DNA. 
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3.2. Introduction 
Varicella-zoster virus (VZV), also known as Human herpesvirus 3 is a highly 
cell-associated human alphaherpesvirus that causes chicken pox (varicella) upon 
infection of naïve individuals (2). During primary infection, VZV is able to establish 
latency in cranial nerves as well as dorsal root and autonomic ganglia, where it 
remains dormant until a reactivation event occurs (8). Reactivation of VZV occurs 
primarily in the elderly or immunocompromised individuals and results in the 
development of shingles (herpes zoster), which is often associated with severe pain 
and postherpetic neuralgia (1).  
The VZV genome, the smallest among the human herpesviruses, is approximately 
125 kbp in size and encodes at least 70 unique open reading frames (ORFs) (1). As has 
been reported for all alphaherpesviruses, the VZV genome consists of two unique 
regions, the unique long (UL) and unique short (US) segment, each flanked by inverted 
repeat regions (TRL, IRL, TRS, IRS) (6). In contrast to herpes simplex virus type 1 
(HSV-1), the prototype alphaherpesvirus, VZV contains only very short repeats (88 
bp) on either end of the UL (5). During alphaherpesvirus replication, four isomers of 
viral DNA are generated, which can be distinguished by the orientation of UL and US 
relative to each other. While all four possible isomers of HSV-1 DNA are represented 
in the virion as equimolar populations, virions produced by VZV and other members 
of the genus Varicellovirus, such as equine herpesvirus type 1 (EHV-1), 
predominantly contain only two isomeric forms of the genome (5, 7, 9, 13, 21). 
Southern blot analysis of VZV virion DNA demonstrated that inversion of the UL 
region is rare (about 5%)  (5) and could also be attributed to a rare circular 
configuration of the genome within the virion (12). A previous report on EHV-1 
suggested that inversion of the UL region in infected cells is common, but that 
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packaging occurs in a directional manner (21). For both VZV and EHV-1, the reason 
for the more or less exclusive orientation of the UL is unknown.  
The organization of the VZV genome is similar to that of HSV-1 and over 90% of 
the VZV ORFs have a counterpart in the HSV-1 genome (1, 11). One of the genes 
without a direct counterpart in HSV-1 is VZV ORFS/L, also known as ORF0, that was 
discovered by Kemble and coworkers (10). No known function is attributed to the 
gene or its product, which is predicted as a 157 amino acid (aa) type 2 transmembrane 
protein with a C-terminal transmembrane domain (11).  The gene is located at the very 
beginning of UL, directly adjacent to the a-like sequences that also includes PacI and 
PacII sites crucial for cleavage and packaging of concatameric VZV DNA (Fig 3.1) 
(11, 17). One potential homologue of ORFS/L is HSV-1 UL56, also a type 2 
transmembrane protein. While UL56 is dispensable for HSV-1 replication in vitro, it 
plays an important role in pathogenicity in vivo (3, 19) although little is known about 
the molecular mechanism of its function. UL56 orthologues are expressed by most 
members of the Alphaherpesvirinae subfamily (24). For example, HSV-2 UL56 
localizes to the Golgi network and interacts with KIF1A, a kinesin motor protein 
suggesting a role in vesicular trafficking (14, 15).  
A previous study of Kemble and coworkers addressed the localization of ORFS/L 
using a rabbit polyclonal antibody and reported that ORFS/L is localized to the 
cytoplasm (11) Furthermore, ORFS/L was found to be expressed in skin lesions of 
individuals as well as neurons of a dorsal root ganglion during virus reactivation. 
Recently, deletion of aa29 to aa157 of ORFS/L was shown to have an effect on viral 
replication in vitro and in vivo in the SCID-hu mouse model (26). However, it still 
remains unknown whether the growth defect is dependent on ORFS/L gene function 
or is due to the deletion of another critical sequence element.  
In this study, we demonstrate that ORFS/L localizes to the Golgi network in infected 
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and transfected cells, suggesting that it is a true functional orthologue of HSV-2 UL56. 
In addition, we could prove that the ORFS/L gene product is important for efficient 
VZV replication. We also identified a 5′ region of ORFS/L that is essential for 
replication and plays a role in cleavage and packaging of viral DNA, previously 
suggested by Davison and colleagues (5). Since this essential region has no homology 
to the opposite end of UL, it could provide an explanation for the almost exclusive 
packaging in VZV virions of two viral DNA isomers with an invariable UL 
orientation. 
 
3.3. Material and Methods 
Cells and Viruses. Human melanoma cells (MeWo) were grown and maintained 
in growth medium (minimal essential medium (MEM) supplemented with 10% fetal 
bovine serum (FBS), 100 U/ml penicillin and 0.1mg/ml streptomycin) at 37°C under a 
5% CO2 atmosphere. Wild-type and mutant viruses were reconstituted, grown and 
amplified on MeWo cells by co-cultivation of infected with uninfected cells at a ratio 
of 1:2 to 1:5.  Virus stocks were frozen in growth media supplemented with 8% 
dimethyl sulfoxide (DMSO) and stored in liquid nitrogen. 
Generation of ORFS/L mutants and revertants via en passant mutagenesis. 
Mutants with a deletion of ORFS/L (∆aa1-157), a start codon knockout (aa1stop) in 
which the ATG was replaced by a stop codon (TAG), a C-terminal deletion (∆aa34-
157), a stop codon insertion at amino acid position 34 (aa34stop) or with an HA-
tagged ORFS/L (S/L_cHA) were generated based on pP-Oka, an infectious bacterial 
artificial chromosome (BAC) clone of the P-Oka strain (22), via two-step red-
mediated en passant mutagenesis as described previously (23). In order to generate 
revertants of the respective ORFS/L mutants, a transfer vector was generated. Briefly, 
a region containing ORFS/L and flanking sequences was amplified from pP-Oka by 
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polymerase chain reaction, cloned into the pcDNA3.1 TOPO vector (Invitrogen) and 
termed prORFS/L. The aphAI-I-SceI cassette was amplified from pEPkan-SII (23) and 
inserted into prORFS/L using a unique EcoRI restriction site within ORFS/L resulting 
in plasmid prORFS/L-aphAI-I-SceI. The entire rORFS/L-aphAI-I-SceI cassette was 
amplified and used for two-step Red-mediated mutagenesis. Revertant viruses of 
∆aa1-157, ∆aa1stop, ∆aa34-157 and ∆aa34stop were termed ∆aa1-157-rev, ∆aa1stop-
rev, ∆aa34-157-rev and ∆aa34stop-rev, respectively. All clones were confirmed by 
PCR and DNA sequencing of the ORFS/L region (Fig. 3.1A) as well as multiple 
restriction fragment length polymorphism analyses (RFLP) to ensure the integrity of 
the genome (data not shown). All oligonucleotides used are given in Table 3.1.  
Reconstitution of VZV from BAC DNA.  BAC DNA used for transfection was 
isolated with the Qiagen Midiprep system according to the manufacturer's (Qiagen) 
instruction. Subsequently, MeWo cells were transfected with Lipofectamin 2000 
(Invitrogen) as described previously (22).  Briefly, 1 µg BAC DNA was co-transfected 
with 200 ng pCMV62, a plasmid, which contains the VZV IE gene ORF62 under the 
control of a CMV promoter (kindly provided by Dr. Kip Kinchington, University of 
Pittsburgh Medical School). The DNA-lipofectamin solution was added onto the cells 
and incubated for 4 h. Transfection medium was then replaced with growth medium. 
Resulting viruses were termed v∆aa1-157, v∆aa1-157-rev, v∆aa1stop, v∆aa1stop-rev, 
v∆aa34-157, v∆aa34-157-rev, v∆aa34stop and vS/L_cHA.  
Multi-step growth kinetics and plaque size assay. 1x106 MeWo cells were 
inoculated with 100 plaque-forming units (pfu) of cell-associated viruses. For multi-
step growth kinetics, infected cells were trypsinized on days 1, 2, 3, 4 and 5 post 
infection (p.i.) and titrated in 10-fold dilutions with fresh MeWo cells and the number 
of plaques determined by indirect immunofluorescence using an anti-gB antibody (US 
Biological). Three independent experiments were performed in triplicates. For plaque  
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Table 3.1. Primers used for cloning and mutagenesis. Underlined sequences indicate 
restriction enzyme sites. Bold indicates mutated sequences. 
CTAAGAATTCGCAAATGCTGTGTACCGGCTAGGGATAACAGGGTAATCGATTTforprORFS/L-
aphAI-I-SceI TTGCGAATTCTTAGAAAAGCCAGCTGAAGTCTGGCCAGTGTTACAACCAATTAACCrev
ATGGGATTTTTTGCCGGGfor
pCDNA-ORFS/L
TGTAGTTGAGTTGGGAGGTTCCTC rev
GTCCACCCCTCGTTTACTGCTCGGATGGCGACCGTGCACTAGTCCCGCCGACCTGGG
ACCCTAGGGATAACAGGGTAATCGATTTfor
∆aa34 stop 
GACGACGTGAGGGTGACCGGCGGGGTCCCAGGTCGGCGGGACTAGTGCACGGTCG
CCATCCGGCCAGTGTTACAACCAATTAACCrev
CCGTTTTTCCCGAGGAACCTCCCAACTCAACTACATATCCGTATGATGTGCCGGATTA
TGCGTGAAACTAGGGATAACAGGGTAATCGATfor
S/L_cHA
GAATAAATACCTTCCCCTTCCGGACAGTAGTTTCACGCATAATCCGGCACATCATACG
GATATGTAGGCCAGTGTTACAACCAATTAACCrev
AGCGACCCCACCTCCCCfor
prORFS/L
CGACAAGCTGCAAGCGAGAArev
GACGCACCGGGGTCATCforSouthern probe
VZV terminus TGTAGTTGAGTTGGGAGGTTCCTCrev
GCAAGCGAGAATAAATACCTTCCCCTTCCGGACAGTAGTTTCAGTGCACGGTCGCCAT
CCGAGCGCCAGTGTTACAACCAATTAACCrev
GCGTCCACCCCTCGTTTACTGCTCGGATGGCGACCGTGCACTGAAACTACTGTCCGG
AAGGGGTAGGGATAACAGGGTAATCGATTTfor
∆aa34-157 
GTTAAAGGCTGGCGGGGGGGGTTTCCCGGCAAAAAATCCCCTACCCCCCCGATGGTC
GCCCCGCGCCAGTGTTACAACCAATTAACCAArev
CCCCACCTCCCCGCGCGTTTGCGGGGCGACCATCGGGGGGGTAGGGGATTTTTTGC
CGGGAAACCTAGGGATAACAGGGTAATCGATTTAfor
∆aa1 stop 
GCAAGCGAGAATAAATACCTTCCCCTTCCGGACAGTAGTTTCACCCCCCCGATGGTCG
CCCCGCGCCAGTGTTACAACCAATTAACCrev
CCCACCTCCCCGCGCGTTTGCGGGGCGACCATCGGGGGGGTGAAACTACTGTCCGG
AAGGGTAGGGATAACAGGGTAATCGATTTATTC for
∆aa1-157 
sequence (5' → 3')Construct name
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size assays, cells were fixed 6 days p.i., stained, and plaques imaged with a digital 
camera (Zeiss Axiovert 25 and Axiocam). Areas of 60 individual plaques were 
evaluated with the Axiovision software (Zeiss).  
Generation of ORFS/L expression plasmids. ORFS/L was amplified from pP-
Oka and inserted into pcDNA3.1/V5-His TOPO vector (Invitrogen). The resulting 
plasmid was sequenced and termed pORFS/L-His. It was then transfected with 
Lipofectamin 2000 according to the manufacturer’s recommendation (Invitrogen).  
Indirect immunofluorescence labeling and confocal microscopy. MeWo cells 
were fixed with 3% paraformaldehyde (PFA) and permeabilized with 0.1% saponin 48 
h after infection or transfection. Cells were stained with mouse monoclonal anti-
GM130 antibody (BD Transduction Laboratories), rabbit polyclonal anti-HIS 
antibodies (Genscript Cooperation) or rabbit polyclonal anti-HA antibodies (Zymed 
Laboratory) at 1:200 dilutions. Secondary antibodies, including AlexaFluor568-
conjugated goat anti-mouse and AlexaFluor488-conjugated goat anti-rabbit 
(Molecular probes) were diluted 1:1,000. Cells were washed with PBS and mounted 
with DAPI Vectashield (Vector Laboratories). Cells were examined using a SP5 
confocal microscope system (Leica). Collected images were arranged using Photoshop 
7.0 (Adobe).  
Prediction software. NetStart 1 for vertebrates  was used to predict translation 
initiation sites of ORFS/L (http://www.cbs.dtu.dk/services/NetStart/) (18). N- and O-
glycosylation (http://www.cbs.dtu.dk/services/NetNGlyc/ and http://www.cbs.dtu. 
dk/services/NetOGlyc/) sites were predicted using NetNGlyc 1.0 and NetOGlyc 3.1. 
The presence of signal peptides for ER translocation was analyzed with SignalP 3.0 
(http://www.cbs.dtu.dk/services/SignalP/). Myristoylation were predicted with 
Myristoylator program (http://ca.expasy.org/tools/myristoylator/).  
Cleavage assay. 1x107 MeWo cells were infected with 1x104 pfu of vP-Oka, 
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v∆aa1stop or v∆aa1stop-rev and harvested at the time of complete cytopathic effect as 
observed after about 48 h, 72 h or 48 h respectively and documented via bright field 
microscopy. Cells were washed with ice-cold PBS and lysed in buffer A (10mM Tris 
pH7.4, 10mM NaCl, 3mM MgCl2, 0.5% NP40). Either purified nuclei or whole cell 
lysates were digested with proteinase K (Qiagen) in the presence of 1% SDS and 5 
mM EDTA, and DNA was purified by phenol/chloroform extraction (20). Equivalent 
amounts of purified nuclear or whole cell DNA were digested with BamHI overnight 
and separated by agarose gel electrophoresis. Southern blot analysis allowed the 
detection of VZV terminal fragments using a digoxigenin-labeled probe, generated 
with the PCR Dig Synthesis kit (Roche) according to manufacturer’s instruction. 
Oligonucleotides used for amplification are given in Table 3.1. Southern blot signals 
were detected by chemiluminescence as recorded with a Chemi-Genius Bio Imaging 
System and quantified with the GeneTool software (Syngene, Cambridge, UK). 
 
3.4. Results  
Analysis of ORFS/L in infected cells.  ORFS/L, predicted as a 157 aa protein, 
harbors two alternative start codons (29 aa and 51 aa). In order to identify protein 
species generated by this open reading frame, we inserted a HA-tag at the C-terminus 
(pS/L_cHA) in pP-Oka, an infectious BAC clone of the P-Oka strain (Fig 3.1A and B) 
(22). Multi-step growth kinetics and plaque size assays demonstrated that S/L_cHA 
virus (vS/L_cHA) is capable of replicating with kinetics comparable to those of 
parental BAC-derived vP-Oka, indicating that HA-tag insertion had no effect on viral 
replication in vitro (Fig. 3.2A and B). Western blot analysis of vS/L_cHA infected 
MeWo cells revealed that ORFS/L is expressed as a single species of about 18 kDa, 
corresponding well to the predicted molecular mass of the full-length, 157 amino acid 
(aa) protein (Fig. 3.1C). Protein predictions programs (Myristoylator, SignalP 3.0,  
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Figure 3.1. Overview of the VZV ORFS/L genomic region and the generated 
mutants. A) Schematic representation of the VZV genome with a focus on the terminal 
region containing ORFS/L. Scale bars provide an accurate measure of the genome and 
the expanded region. B) Overview of the mutants generated in the ORFS/L region. 
The X indicates the deletion of the corresponding region. Arrows indicate the loci of 
stop codon or HA-tag insertion.   
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Figure 3.2. Growth properties of vS/L_cHA and size determination of ORFS/L. A) 
Multi-step growth kinetics of vS/L_cHA and vP-Oka. Shown are the means of three 
independent experiments including the standard error (error bars). B) Plaque size 
measurements of vS/L_cHA and vP-Oka. Shown are relative average plaque areas of 
60 individual plaques with standard deviations (error bars), with the sizes of vP-Oka 
plaques set at 100%. C) Western blot analysis of cells infected with vP-Oka (lane 1) or 
vS/L_cHA (lane 2). Arrows indicate the predicted molecular mass of the unmodified 
ORFS/L protein when initiated from the first (aa1), second (aa29) or third methionine 
codon (aa51). 
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NetNGlyc 1.0 and NetOGlyc 3.1) indicated that ORFS/L is not myristoylated and 
posseses an ER-localization signal, which is a prerequisite for modification in the ER 
or Golgi. Our data, therefore, suggest that ORFS/L is exclusively expressed as the full-
length protein and that that the two alternative start codons (aa 29 and aa 51) are not 
used for translation initiation.  
  ORFS/L localizes to the trans-Golgi network (TGN) in infected and 
transfected cells.  To determine the subcellular localization of ORFS/L in VZV 
infected cells, we infected MeWo cells with vS/L_cHA. Confocal microscopy 
revealed that ORFS/L colocalizes with GM130, a marker for the Golgi apparatus, in 
infected MeWo cells (Fig. 3.3A, upper panel). Besides the Golgi network, ORFS/L 
was found to localize to the nuclear envelope upon syncytia formation (Fig. 3.3A, 
middle and lower panels). To address the question whether localization of ORFS/L to 
the Golgi network is dependent on other viral proteins, we determined the localization 
of ORFS/L in transfected cells. MeWo cells were transfected with pcDNA-ORFS/L-
His. Similar to the situation in infected cells, ORFS/L was localized to the Golgi 
network after expression of the His-tagged protein under a strong herpesvirus (CMV-
IE) promoter.  We concluded, therefore, that localization of the ORFS/L protein to the 
Golgi apparatus is independent of the presence of other viral proteins (Fig. 3.3B) and 
that ORFS/L likely represents an orthologue of HSV-1 UL56.  
Deletion of the entire ORFS/L is lethal for VZV replication in vitro.  Previously, a 
recombinant virus containing a deletion of the C-terminal 129 aa, downstream of the 
second start codon of ORFS/L was reported to have an effect on viral replication in 
vitro and in vivo (26). To confirm the role of ORFS/L in VZV replication, we deleted 
the entire ORF (aa 1 to aa 157) corresponding to base pair (bp) 88 to 558 of pP-Oka  
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Figure 3.3. Localization of ORFS/L in infected and transfected cells. A) Localization 
of ORFS/L (green) with GM130 (red), a marker for the Golgi apparatus, and DAPI 
(blue) is shown for single infected MeWo cells (upper panel) or in syncytia (middle 
panel). The lower panel shows a focus on the nuclei within a syncytium that confirms 
a colocalization of ORFS/L and the nuclear envelope. Scale bars correspond to 30 µm 
(upper panel) and 100 µm (middle panel). B) MeWo cells were transfected with 
expression plasmid pORFS/L-His and analyzed 48 h after transfection. ORFS/L 
(green) and GM130 (red) were detected with indicated antibodies. The infected and 
transfected cells are representative for the cell population. Scale bars correspond to 20 
µm. 
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(Fig. 3.1) (22). In addition, a revertant BAC clone (p∆aa1-157rev) was generated in 
which the original ORFS/L sequence was restored. Subsequently, the constructs were 
transfected into MeWo cells resulting in the reconstitution of recombinant viruses 
v∆aa1-157 and v∆aa1-157rev. Upon virus reconstitution, wt independent v∆aa1-157 
clones exhibited a severe replication defect while the revertant virus grew with 
kinetics that were virtually indistinguishable from those of parental vP-Oka. Plaque 
size measurements confirmed this significant growth defect (Fig. 3.4A and B). The 
replication defect of both v∆aa1-157 clones was so severe that the viruses could not be 
amplified by passaging.  
  ORFS/L gene product plays a role in replication in vitro. To determine 
whether the observed growth effect was due to the lack of the ORFS/L gene product or 
an essential DNA element within ORFS/L, we generated a series of additional mutant 
viruses. In order to abrogate ORFS/L gene expression, we either replaced the first start 
codon (vaa1stop) or the codon for amino acid 34 (vaa34stop), just downstream of the 
second start codon, with a stop codon (Fig 3.1). We also generated a C-terminal 
deletion of aa34 to 157 (v∆aa34-157) similar to previous reports (11, 26). In addition, 
revertant viruses of vaa1stop (vaa1stop-rev) and v∆aa34-157 (v∆aa34-157-rev) were 
generated. Multi-step growth kinetics revealed that vaa1stop, vaa34stop and v∆aa34-
157 were significantly impaired in viral replication when compared to vP-Oka or 
revertant viruses (Fig 3.5A). While vaa34stop and v∆aa34-157 replication was 
reduced by about 5-fold, vaa1stop was reduced by about 10-fold. In order to confirm 
the growth defect, we performed plaque size assays. In agreement with the multi-step 
growth kinetics, vaa1stop, vaa34stop and v∆aa34-157 showed a significant defect in 
plaque formation when compared to vP-Oka or revertant viruses (Fig. 3.5B). Plaque 
areas of vaa1stop, vaa34stop and v∆aa34-157 were reduced by 69%, 45% and 38%, 
respectively, when  
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Figure 3.4. Growth properties of viruses lacking the entire ORFS/L. A) Plaque size 
measurements of v∆aa1-157 (clones 1 and 2), vP-Oka and revertant v∆aa1-157 
generated from clone 1. Twenty individual plaque areas were measured and are shown 
as means (vP-Oka plaques were set at 100%) with standard deviations (error bars).  
Plaque areas induced by ∆aa1-157 mutants were significantly reduced (p<0.0001) 
when compared to those of parental vP-Oka or or the revertant virus using Student’s t-
test. B) Representative plaque images for v∆aa1-157 (clones 1 and 2), vP-Oka and 
v∆aa1-157-rev. Scale bars correspond to 200 µm.  
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compared with parental vP-Oka or the revertant virues. Replication defects seen with 
both stop codon mutants confirmed that the ORFS/L gene product is crucial for 
efficient VZV replication. The results of the experiments also led us to conclude that 
the sequence encoding the amino-terminal 33 aa of ORFS/L contain an essential 
sequence element that does not directly relate to the function of the ORFS/L protein.  
Cleavage defect of vaa1 stop contributes to its growth defect. To elucidate 
whether the observed differences in viral replication of vaa1stop and vaa34stop (Fig. 
3.5A and B) was due to a structural function of the extreme 5′-end of ORFS/L, we 
examined the cleavage and packaging of VZV genomes from concatemeric replication 
intermediates in cells infected with mutant or parental viruses. We infected MeWo 
cells with vaa1stop, vaa1stop-rev or vP-Oka, harvested the cells at 90-100% 
cytopathic effect, prepared nuclear or whole cell DNA, digested it with BamHI and 
probed for the genomic termini (Fig 3.6A). While vaa1stop-rev viruses showed a 
cleavage pattern comparable to parental vP-Oka, viral DNA in cells infected with the 
vaa1stop showed a significant increase in uncleaved VZV termini in whole cell DNA 
(Fig. 3.6B). Since the quantity of cytosolic virions has an effect on the amount of 
cleaved termini, we also analyzed nuclear DNA. A comparable increase in uncleaved 
VZV termini was observed in nuclear preparations (data not shown). The relative 
quantity of uncleaved genomes was increased by more than 3.6-fold, indicating that 
the 5′-region of ORFS/L is involved in cleavage of unit-length genomes from 
concatameric replicative form DNA, before packaging into newly formed 
nucleocapsids. This reduction in DNA cleavage could subsequently result in impaired 
packaging of VZV genomes, which would account for the more severe growth defect 
of vaa1stop when compared to vaa34stop or v∆aa34-157. From the results we, 
therefore, concluded that the ORFS/L 5′ region contains an essential sequence element 
and that this element is likely involved in cleavage and packaging of viral DNA. 
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Figure 3.5. Growth properties of a panel of ORFS/L mutants. A) Multi-step growth 
kinetics of indicated viruses. Virus replication of vaa1stop, vaa34stop and v∆aa34-157 
was significantly reduced (p<0.05) at indicated time points (asterisk)   when compared 
to vP-Oka or corresponding revertant virus as determined using the Student’s t-test. B) 
Plaque size measurements of indicated viruses. Plaque areas of vaa1stop, vaa34stop 
and v∆aa34-157 were significantly reduced (p<0.001) when compared to those of vP-
Oka (set to 100%) or the corresponding revertant virus as determined by Student’s t-
test. Shown are means of 60 individual plaques per virus and standard deviations 
(error bars). 
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Figure 3.6. Cleavage of the viral genome in cells infected with mutant virus. A) 
Schematic representation of the terminal fragments, TRS and UL, generated after 
restriction enzyme digestion with BamHI. The probe used to detect the genomic 
termini by Southern blotting is indicated. The scale bar provides an accurate measure 
of the sizes of the fragments expected after cleavage and of the probe. B) Cleavage 
analysis of vP-Oka (lane 2), vaa1stop (lane 3) and vaa1stop-rev (lane 4). The P-Oka 
BAC (lane 1) served as a standard for uncleaved termini. The Southern blot shown is 
representative of three independent experiments. C) Quantification of band intensities 
of three independent cleavage assays. The ratio of uncleaved and cleaved DNA is 
shown relative to vP-Oka. The relative amount of uncleaved termini of vaa1stop was 
significantly increased (p<0.05) when compared to vP-Oka and vaa1stop-rev as 
determined by Student’s t-test. 
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3.5. Discussion 
Although the molecular tools available to study VZV replication in vitro and in 
vivo have considerably improved over the past decade, the functions of several of the 
70 unique VZV ORFs still remain unknown. While sequence similarities between 
herpesviruses ORFs can often provide valuable information on protein localization 
and function, such predictions only provide testable hypotheses but no formal proof of 
the role these proteins or genetic elements play in related viruses. Furthermore, some 
of the VZV ORFs, such as ORFS/L, ORF1, ORF2, ORF13, ORF32 and ORF57, do 
not have known orthologues in the prototype alphaherpesvirus, HSV-1 (10).   
For example, the function of ORFS/L, an ORF located at the very end of the UL, 
remains enigmatic.  Previously, a report demonstrated that a deletion of the C-terminal 
portion of ORFS/L resulted in a viral growth defect in vitro and in vivo (26). It has 
remained unclear, however, whether this defect is due to ORFS/L gene function or a 
critical sequence element that is independent of protein function. A second study also 
suggested that the ORFS/L protein localizes to the cytoplasm.  Here, we chose to 
revisit both ORFS/L function and the localization of the encoded protein and also 
sought to dissect putatively overlapping functions of this genomic region.  We 
surmised that important functions are attributable to nucleotide sequences specified in 
this region, which has close proximity to the DNA processing elements involved in 
cleavage and packaging of the viral DNA in newly formed nucleocapsids.  
We first addressed the subcellular distribution of the ORFS/L protein and were 
able to demonstrate that it localizes to the Golgi apparatus in infected and transfected 
cells, which supports previous bioinformatic predictions that suggested it is 
homologue of the HSV-1 and HSV-2 UL56 gene product. Besides its subcellular 
localization, the position of ORFS/L within the VZV genome, in close proximity to 
ORF3 representing the VZV homologue of UL55, also supports this assumption. In 
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addition, the ORFS/L protein shares 20% sequence identity with the UL56 gene of 
HSV-1 and -2 and contains two of the three conserved PY motifs (L/PPXY).  The PY 
motifs of HSV-2 UL56 were shown to facilitate binding to Nedd4, an E3 ubiquitin 
ligase involved in protein sorting and trafficking (4, 24, 25).  Although we show here 
that subcellular localization of the ORFS/L protein is consistent with an involvement 
of Nedd4-dependent sorting, further studies will be necessary to analyze the exact 
molecular functions of the ORFS/L product and its interaction with cellular proteins.  
The putative interaction partners include KIF1A, a member of the kinesin family that 
is involved in vesicular trafficking along microtubules and for which an interaction 
with the HSV-2 UL56 product was identified (15).   
Western blot analysis suggested that the P-Oka ORFS/L is solely expressed as a 
protein of 18 kDa in size, and that the alternative start codons present in the ORF are 
not used during infection. In addition, post-translational modifications that could 
account for size differences, such as myristoylation, N- and O-glycolylations seem 
unlikely based on in silico predictions. The lack of an ER signal peptide indicates that 
ORFS/L is likely not translated at the rough ER or translated or modified in the ER or 
Golgi network.  Similar to the HSV-1 and HSV-2 UL56 proteins, the VZV ORFS/L 
product is predicted to encode a C-terminal-anchored, type II transmembrane protein. 
This protein class does not possess an N-terminal signal sequence that would provide a 
signal for membrane insertion.  Instead, type II transmembrane proteins contain a C-
terminal hydrophobic region facilitating insertion and orienting the N-terminus of the 
protein towards the cytoplasm (16). In the case of the HSV-2 UL56 protein, the C-
terminal hydrophobic region was indeed shown to be responsible for membrane 
insertion and its localization to the Golgi apparatus (14, 15).  
It is notable that analysis of genome sequences of several other VZV strains 
suggested that ORFS/L translation might not be initiated from the first start codon, 
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because a frame shift mutation reported to occur immediately downstream of the first 
AUG would terminate translation prematurely. However, this frame shift was 
identified to be caused by an additional cytosine within a stretch of eight consecutive 
cytosines, which could be a sequencing error caused by polymerase slippage. In 
contrast to the 17 wild type VZV strain sequences available in GenBank 
(http://www.ncbi.nlm.nih.gov/), the vaccine strains vOka, VariVax and VarilRix, have 
a mutation in the stop codon that extends the open reading frame by 276 bp (92 aa). 
This extension could affect the insertion of ORFS/L into membranes and as such 
contribute to the attenuated phenotype of the vaccine viruses. More detailed sequence 
analyses and identification of whether or not ORFS/L is expressed in the strains in 
question will be necessary to confirm or refute the potential variation with respect to 
ORFS/L expression discussed for VZV strains other than P-Oka.  
Mutations of the first codon and immediately downstream of the second start 
codon confirmed that the ORFS/L gene product plays an important, albeit not 
essential, role in VZV replication. The involvement in vesicular trafficking, as shown 
for HSV-2 UL56, could account for the growth defect observed in cultured MeWo and 
HFF cells.  In contrast, partial and complete deletions of ORFS/L sequences revealed 
that the 5′ region of ORFS/L is essential for replication.  Analysis of the status of viral 
DNA in cells infected with the mutant viruses showed that a sequence element 
contained in ORFS/L is involved in cleavage and packaging of single unit genomes 
from concatemeric replication intermediates. Intriguingly, this sequence that we 
showed is essential for efficient cleavage and packaging of viral DNA is not present at 
the opposite end of the UL. Consequently, inversion of the UL would theoretically lead 
to a potentially lethal cleavage and packaging defect, which may explain why there is 
preferential packaging of viral DNA with only one orientation of the UL.  The 
asymmetry of the ends of the VZV UL region was first detected and discussed by 
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Davison and coworkers, who predicted a cleavage element within the UL region that 
resides at least 90 bp from the genomic terminus, which exactly corresponds to the 5’ 
region of ORFS/L. This hypothesis is also in agreement with data suggesting 
directional packaging of EHV-1 into virions, with the EHV-1 genomic organization 
being very similar to that of VZV (21). 
In conclusion, our study provides the first evidence that the ORFS/L gene product 
plays a role in VZV replication and that the 5′ region is involved in cleavage and 
packaging. Further studies of ORFS/L function and its potential interaction partners 
will shed light on its detailed role in VZV replication. In addition, defining the 
essential sequence elements within the 5′ region of ORFS/L may increase the 
understanding of its role in cleavage and packaging as well as the almost exclusive 
orientation of the UL in VZV virions.  
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4.1. Abstract  
Telomerase is a ribonucleoprotein complex involved in the maintenance of 
telomeres, a protective structure at the chromosome termini. The enzyme complex 
contains two main components, telomerase reverse transcriptase (TERT), the catalytic 
subunit, and the telomerase RNA (TR), which serves as a template for the addition of 
telomeric repeats (TTAGGG)n. Marek’s disease virus (MDV), an oncogenic 
herpesvirus, encodes a TR homologue, viral TR (vTR), which significantly contributes 
to MDV-induced lymphomagenesis. As recent studies suggest that TRs possess 
telomerase-independent functions, we investigated if the tumor-promoting capacity of 
vTR is dependent on formation of a functional telomerase complex. We show that 
vTR-TERT interaction and telomerase activity was efficiently abrogated by the 
disruption of the vTR P6.1 stem-loop (P6.1mut). Recombinant MDV carrying the P6.1 
stem-loop mutation were generated and tested in the natural host, the chicken, in 
which MDV readily induces fatal lymphomas. In contrast to viruses lacking vTR, all 
animals infected with P6.1mut viruses developed MDV-induced lymphomas, but onset 
of tumor formation was significantly delayed. P6.1mut viruses induced enhanced 
metastasis, indicating functionality of non-complexed vTR in tumor dissemination. 
We discovered that vTR interacts with RPL22, a cellular factor involved in T-cell 
development and virus-induced transformation.  The interaction is enhanced in the 
presence of vTR harboring the P6.1 stem-loop mutation when compared to wild-type 
vTR.  Our study provides the first evidence that expression of TR, in this case encoded 
by a herpesvirus, is pro-oncogenic in the absence of telomerase activity. 
 
 
 
 
90 
4.2. Author Summary  
The telomerase complex with its two main components, telomerase reverse 
transcriptase and telomerase RNA, plays an important role in telomere maintenance 
and is involved in tumor development. Recent studies suggest telomerase RNAs can 
function independently of the telomerase complex, and possibly promote tumor 
development. Here we demonstrate that vTR, a herpesvirus encoded telomerase RNA, 
serves two distinct functions in MDV-induced tumor formation. The first is dependent 
on increased telomerase activity, which is crucial for rapid onset of lymphomas in 
infected animals.  vTR becomes part of the telomerase complex and contributes to the 
survival of rapidly dividing transformed cells. The second function of vTR is entirely 
independent of telomerase action and is crucial for tumor formation and metastasis. 
This latter function is likely a consequence of vTR-mediated gene regulation that is at 
least in part controlled by interaction of vTR with RPL22, a cellular factor involved in 
T-cell development and virus-induced transformation. Taken together, our study 
demonstrates that telomerase RNA encoded by a herpesvirus is directly involved in 
tumor formation in vivo, in a fashion that is largely independent of its function within 
an active telomerase complex. 
 
4.3. Introduction 
Telomerase is a multi-component ribonucleoprotein complex. One of its main 
functions is the maintenance of telomeres, a protective structure at the termini of linear 
chromosomes. The telomerase complex consists of two essential core components, 
telomerase reverse transcriptase (TERT) and telomerase RNA (TR), which serves as a 
template for the catalytically active subunit in the elongation of telomeric repeats 
(TTAGGG)n at the end of chromosomes (11). TR contains four structural domains, 
which are highly conserved regions (CR) in all vertebrates: i) the pseudoknot (core) 
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domain, containing the template sequence (CR1); ii) the H/ACA box and iii) the 
conserved region (CR) 7 domain. Both the H/ACA box and CR7 are essential for TR 
stability and localization; and iv) the CR4-CR5 domain, which is required for efficient 
TR-TERT complex formation, and subsequent telomerase activity and processivity (7, 
9). An essential structure within the CR4-CR5 domain is the P6.1 stem-loop. Base 
pairing of the P6.1 stem is completely conserved in all vertebrates. Disruption of the 
base pairing of the P6.1 stem was shown to interfere with proper TR-TERT interaction 
and resulted in absent telomerase activity in vitro and in vivo (4, 7, 33). In addition, 
the P6.1 stem-loop was shown to interact with conserved sequences of the template 
region CR1, which also plays a critical role in the catalytic activity of the telomerase 
complex (33).  
Telomerase activity is tightly regulated and varies amongst cell types. While it is 
commonly up-regulated in germ-line, stem and cancer cells, it is absent in most 
somatic cells (28). The absence of telomerase activity often leads to progressive 
telomere shortening, known to initiate cellular senescence and irreversible cell cycle 
arrest (2). Several tumor-inducing viruses have evolved strategies to evade and subvert 
this mechanism of cellular senescence, mainly via the up-regulation of TERT, which 
was shown to be the limiting factor of telomerase activity in some organisms, such as 
the human and the chicken (2). It has been suggested that up-regulation of TERT 
expression and provision of more active telomerase increases the proliferative 
potential of cells persistently infected with virus, which in turn might be beneficial to 
accumulating genetic alterations and transformation after infection (2). 
One of the most remarkable viruses with respect to the efficiency of the induction 
of fatal tumors is Marek’s disease virus (MDV), a lymphotropic alphaherpesvirus, that 
causes Marek’s disease (MD) in chickens, characterized by neurological disorders, 
immune suppression and, primarily, malignant T cell lymphomas (32). The rapid onset 
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of MD-induced lymphomas, as early as 2 weeks post-infection, and high tumor-
induced mortality (90-100% in susceptible animals), suggests a direct involvement of 
virus-encoded oncogenes in the process. The major MDV oncogene, meq, encodes a 
basic leucine zipper (bZIP) transcription factor (TF) that was shown to interact with 
Rb, cdk2 and p53, proteins involved in cell-cycle control, and several cellular TFs 
including c-Jun, c-Fos and c-Myc, an oncogene  known to regulate TERT expression 
(6, 24). In addition, and as a unique feature, the MDV genome harbors two copies of 
its own TR subunit, termed viral TR (vTR), that shares 88% sequence identity with 
chicken TR (chTR), contains all four conserved structural TR domains, and was likely 
acquired from the chicken genome (9). The 180-kbp linear, double-stranded DNA 
genome of MDV consists of a long (L) and short (S) unique region (UL and US) 
flanked by terminal (TRL or TRS) and internal (IRL or IRS) inverted repeats. Both vTR 
copies are located in the repeats flanking the UL, TRL and IRL. Besides the presence of 
vTR in the TRL and IRL, MDV also contains two sets of tandem repeats in very close 
proximity to the genomic termini that represent perfect telomeres (18).  
vTR is expressed during both lytic and latent MDV infection. It is functionally 
active and was shown to efficiently induce higher telomerase activity and processivity 
with respect to telomere elongation in vitro than its cellular homologue, chTR (10, 
32). Although dispensable for lytic replication in vitro and in vivo, vTR is required for 
efficient MDV-induced tumorigenesis, as MDV mutants lacking both copies of vTR 
were severely impaired in lymphoma formation and dissemination (32).  
Recent reports suggest that both TERT and TR may also have roles in 
tumorigenesis aside from their role the maintenance of telomere length in rapidly 
dividing cells (3, 5, 20). For example, human TR has been shown to restrain ATR 
activity, a factor in the DNA damage response pathway, in a telomerase-independent 
fashion allowing the survival of cells after cellular stress such as UV radiation (16). 
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Furthermore, knockdown of TR in human cancer cells induced rapid changes in the 
global gene expression profiles that were independent of telomere maintenance and 
DNA damage responses. Induced changes in expression levels included genes 
involved in cell cycle progression (Cyclin G2 and Cdc27) and adhesion (integrin αV), 
that may have an effect on MDV pathogenesis and tumorigenesis as well (20).  
Similarly, expression of  vTR in the chicken fibroblast DF-1 cell line that does not 
exhibit telomerase activity induced a 2-fold increase of integrin αV expression, 
suggesting a telomerase-independent function for vTR (17, 20, 32).  
A potential interaction partner of vTR is ribosomal protein L22 (RPL22), 
previously shown to interact with human TR (19). Besides associating with ribosomes, 
RPL22 is also involved in T-cell development (1, 22).  T-cells are the target of MDV 
transformation. Epstein-Barr virus (EBV), a herpesvirus that shares many 
pathobiological similarities with MDV, encodes two RNAs termed EBER 1 and 2. 
EBER-1 is highly abundant in latently infected cells (12, 32) and was shown to 
mediate transformation through an RPL22-binding RNA, which was termed EBV 
encoded RNA 1 (EBER-1) (31).  
In order to elucidate whether MDV vTR has functions that are independent of 
telomere maintenance and the formation of a functional telomerase complex, we 
mutated the P6.1 stem-loop present in CR4-CR5 of MDV-encoded vTR. The mutation 
was shown to efficiently abrogate vTR-mediated telomerase activity in vitro. In vivo 
studies analyzing MD incidence, tumor development and dissemination confirmed that 
vTR contains functions dependent and independent of the formation of an active 
telomerase complex. In addition, we identified RPL22 as a novel interaction partner of 
vTR. To our knowledge, the data presented here provide the first in vivo evidence that 
a TR executes functions important for tumor formation that are independent of 
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telomerase activity and likely depend on the alternate usage of RPL22 in the 
transformation process.  
 
4.4. Results and Discussion 
vTR P6.1 stem-loop mutation efficiently disrupts telomerase activity. To 
ensure that the disruption of the vTR P6.1 stem-loop, as previously shown for cellular 
TRs, efficiently abrogates vTR-TERT interaction and consequently telomerase 
activity, we performed gel-based telomere repeat amplification protocol (TRAP) 
assays. Base pairing of the P6.1 stem-loop was disrupted by mutating base pairs (bp) 
295-298 of vTR from 5′-AGAG-3′ to 5′-UCUC-3′ as shown in figure 4.1A. In order to 
confirm the absence of telomerase activity via TRAP assay, in vitro transcription was 
used to generate various vTR’s that were used in the TRAP assays (Fig. 4.1B): wild- 
type (wt) vTR, vTR containing the P6.1 mutation (Fig 4.1A), or, as a negative control, 
vTR containing a mutation in the template sequence (AU5) resulting in the addition of 
(TATATA)n repeats that are not amplified in the TRAP assay. Functional chTERT 
protein was obtained by in vitro transcription of a synthetic cDNA followed by 
translation using a rabbit reticulocyte lysate system (Fig. 4.1C). In order to reconstitute 
the telomerase complex, chTERT was incubated with vTR variants or actin control 
RNA and telomerase activity analyzed by TRAP assay. While telomerase activity was 
readily detected with wt vTR confirming earlier results (10), no TRAP products could 
be detected when vTR was used harboring the P6.1 mutation, the AU5 mutation or 
when negative control RNA was added to the reaction (Fig. 4.1D). Although clearly 
detectable, few TRAP products were obtained with the vTR-TERT combination. The 
relatively low activity of reconstituted vTR-TERT compared with the positive control 
TR could be due to the low TERT levels generated by in vitro 
transcription/translation, the lack of accessory telomerase factors, or a high protein  
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Figure 4.1. Effect of the P6.1 mutation on telomerase activity. A) Schematic of 
the CR4-CR5 domain including a detailed representation of the P6.1 stem-loop. 
Structure of wild-type P6.1 (left) and mutant P6.1 stem-loop (P6.1 mut) (right) is 
shown. Nucleotide changes of the wt P6.1 stem-loop (blue) are shown in red. B) In 
vitro transcribed β-actin control RNA, wt vTR RNA, vTR containing the P6.1 
mutation (P6.1) or a mutation in the template sequence (AU5) was analyzed on a 2% 
denaturing agarose-formaldehyde gel. Expected vTR size is indicated by the black 
arrow. C) Chicken TERT-His was translated in vitro using rabbit reticulocyte lysates 
and subsequently analyzed via Western blotting using an anti-5х-His antibody. The 
expected size of TERT-His is indicated with the black arrow. D) Telomerase activity 
of the in vitro transcribed vTR variants was analyzed using gel based TRAP-assays. 
TRAP products and the internal control (IC) are indicated. The results shown are 
representative for three independent experiments showing similar results. 
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content of the reticulocyte lysates known to reduce TRAP product generation (21). 
Our results clearly demonstrated that the introduced mutation within the vTR P6.1 
stem-loop completely abrogates the formation of an active telomerase complex. 
Construction of MDV bacterial artificial chromosome (BAC) mutants. To 
determine whether the established tumor-promoting function of vTR is dependent on 
the formation of an enzymatically active telomerase complex, we manipulated the 
P6.1 stem-loop in pRB-1B, an infectious BAC clone of the highly oncogenic RB-1B 
MDV strain (Fig. 4.2A) (25). Base pairing of the P6.1 stem-loop was disrupted by 
mutating base pairs (bp) 295-298 of vTR, as described above, by two-step Red-
mediated mutagenesis (30) (Fig. 4.1A). The mutation was introduced into both copies 
of the diploid vTR gene within the MDV genome, and the resulting mutant infectious 
clone was termed pP6.1mut. In addition, a revertant BAC clone (pP6.1rev) was 
generated in which the original sequence was restored in both alleles. All clones were 
confirmed by PCR, DNA sequencing and multiple restriction fragment length 
polymorphism analyses (RFLP) to ensure the integrity of the genome (Fig. 4.2B) 
vTR-TERT interaction and telomerase activity are dispensable for efficient 
lytic viral replication in vitro and in vivo. In order to investigate the effect of the 
P6.1 stem-loop mutation on virus replication in vitro, wt pRB-1B, pP6.1mut and 
pP6.1rev BACs were transfected into chicken embryo cells (CEC) resulting in the 
reconstitution of recombinant viruses termed vRB-1B, vP6.1mut and vP6.1rev. Multi-
step growth kinetics revealed that replication of vP6.1mut was unaffected in vitro 
when compared to that of wt vRB-1B or vP6.1rev (Fig 4.3A). In addition, mutation of 
the P6.1 stem-loop had no effect on plaque sizes induced by the P6.1 virus mutant (Fig 
4.3B). These findings were consistent with previous data on vTR deficient viruses, 
which had shown that vTR is dispensable for lytic virus growth in vitro (32).  
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Figure 4.2. MDV genome organization and P6.1 stem-loop mutation. A) Schematic 
representation of the MDV genome including the unique-short and -long regions (US, 
UL) flanked by terminal and internal repeat regions (TRS, TRL, IRS, IRL). The focus on 
the vTR-containing regions shows the telomeric repeat region present in the MDV 
genome (left), vTR including its conserved regions (CR) 1-8, and the three exons of 
the neighboring vIL-8 gene (right). B) Restriction fragment length polymorphism 
analyses  of pRB-1B (lane 2, 6, 10), vP6.1mut (lane 3, 7, 11) and vP6.1rev (lane 4, 8, 
12) using the indicated restriction enzymes. Lane 1, 5, and 9 show the 1 kb plus ladder 
(Invitrogen) ranging from 2 kbp (lowest band) to 12 kbp (highest band) in 1 kbp 
increments.  
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Figure 4.3. Growth properties of viruses containing the P6.1 stem-loop mutation. A) 
Multi-step growth kinetics of wt vRB-1B, vP6.1mut and vP6.1rev were performed in 
triplicates and are shown as means with standard deviations (error bars). B) Plaque 
size assay. Results are shown for the three recombinant viruses as the relative mean 
plaque area in percent of 100 randomly selected plaques induced by each of the 
viruses with the corresponding standard deviations (error bars). 
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Since efficient lytic replication in vivo is considered a prerequisite for efficient 
lymphomagenesis, we analyzed the replicative potential of the various mutant viruses 
in the natural host. We infected 1-day-old chickens and monitored virus levels by 
qPCR using DNA isolated from whole blood obtained by wing vein puncture until 28 
days post infection (dpi).  MDV is present in peripheral blood mononuclear cells 
(PBMC) and qPCR analyses showed that vP6.1mut replicated in those cells to levels 
that were comparable to those of wt vRB-1B or vP6.1rev (Fig. 4.4A). The results were 
again consistent with published data on the lytic replication of vTR deficient viruses, 
which were shown to be fully capable of robust lytic replication (32). The observed 
dispensability for lytic replication of vTR-TERT interaction and vTR-mediated 
telomerase activity in general can be explained by the fact that the initial virus 
production in chicken B and T cells does not require long-term survival of the host cell 
or host cell proliferation.  Survival of the latently infected host cell is, however, a 
prerequisite for, or consequence of transformation and tumor formation. From the 
results of the experiments on lytic replication of the P6.1mut viruses we concluded 
that viruses containing the P6.1 stem-loop mutation are capable of efficient replication 
in cultured cells in vitro as well as in the target cells in vivo. Therefore, a functional 
vTR-TERT interaction is not needed for replication in vivo, a prerequisite for MDV-
induced disease. 
Onset of MDV-induced lymphoma is delayed in the absence of vTR-TERT 
interaction and vTR-mediated telomerase activity. We have previously shown that 
MD lymphoma formation was significantly reduced in the absence of vTR (32). To 
address whether the observed reduction is dependent on the interaction of vTR with 
TERT, we performed two independent animal experiments in which we monitored the 
temporal occurrence of virus-induced lymphoma in chickens infected with vRB-1B, 
vP6.1mut or P6.1rev. In a trial experiment, we established that abrogation of vTR- 
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Figure 4.4. P6.1 stem-loop mutation does not affect lytic replication in vivo, but 
delays MD incidence. A) qPCR analysis of the viral ICP4 gene and the host iNOS 
gene. Blood samples were taken at 4, 7, 10, 14, 21, and 28 dpi and total DNA was 
extracted. Mean MDV genome copies / 106 blood cells of eight infected chickens per 
group as determined by qPCR analysis are shown with standard deviations (error 
bars). B) 1st animal experiment: MD incidence in percent in chickens infected with 
vRB-1B (n=5), vP6.1mut (n=10) and vP6.1rev (n=8) during the indicated time period 
C) 2nd animal experiment: MD incidence in percent of vP6.1mut (n=22) and vP6.1rev 
(n=20) during the indicated time period. The time to develop MD in 50% of the 
inoculated animals (MD50) is indicated (dashed line) and was significantly increased in 
the P6.1mut group (p=0.0012).  
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mediated telomerase activity markedly delayed the onset of MD lymphomas (Fig 
4.4B). We observed that the time until development of tumors and occurrence of MD 
in 50% of the infected animals (MD50) was increased from 36 dpi in vRB-1B-infected 
chickens (n=5) and 32 dpi in vP6.1rev-infected animals (n=8) to 46 dpi in vP6.1mut-
infected birds (n=10).  
To eliminate subjectivity, in a second animal experiment, we used a double 
blinded approach to examine the onset of clinical signs. In agreement with the results 
of the first animal experiment, MD50 was significantly delayed in vP6.1mut infected 
chickens (49 dpi, n=22) when compared to vP6.1rev expressing wt vTR (32 dpi, n=20) 
(p=0.0012). We hypothesize that the observed delay in the development of 
lymphomas is due to a curtailing of telomerase activity that is caused by the loss of 
enhanced telomere maintenance mediated by vTR. Such enhanced telomere 
maintenance, which was shown in MDV-infected animals (29) and is thought to play 
an important role for the survival of rapidly dividing MDV-transformed cells early in 
the transformation process, is probably mediated by vTR-chTERT interaction. In the 
absence of the P6.1 stem-loop, the interaction can no longer occur, and, therefore, the 
pool of transformed cancer stem cells surviving the initial crisis may be reduced. 
It was notable, however, that, in contrast to viruses lacking vTR (32), all animals 
infected with v6.1mut succumbed to MD before termination of the experiment, 
indicating that vTR has functions independent of the formation of an active telomerase 
complex. From the results of the animal experiments we conclude that the rapid onset 
of MD observed in chickens infected with wt MDV (vRB-1B) or the vP6.1rev virus is 
clearly dependent on telomerase activity that involves vTR-chTERT interaction and 
telomerase activity. Importantly, lymphoma formation and fatal disease outcome is 
efficient even in the absence of enzymatically active telomerase. 
104 
Tumor dissemination is increased in the absence of functional vTR-TERT 
interaction. MDV-induced tumor formation and metastasis were previously shown be 
significantly reduced in the absence of vTR (32). In addition, our earlier findings of 
integrin αV up-regulation mediated by vTR alone suggested that malignant lymphoma 
dissemination may be a result of the action of vTR that is independent of vTR-TERT 
interaction (32). To address whether animals infected with the P6.1mut virus, in which 
vTR-TERT complex formation is absent and most likely more non-complexed vTR 
available, show an increase in dissemination, we enumerated the gross lesions in 
infected birds during necropsies on animals that had succumbed to infection. 
Consistent with our earlier results and the hypothesis that lymphomagenesis and 
metastasis could be largely determined by vTR action alone, disruption of the P6.1 
stem-loop led to a significant increase in the number of solid lymphomas in chickens 
infected with the vP6.1mut virus when compared to vP6.1rev-infected chickens 
(p=0.0016). All vP6.1mut-infected animals developed gross tumors in at least three 
organs (Fig. 4.5A). Furthermore, the average number of organs with solid lymphomas 
was significantly increased from 3.1 in vP6.1rev to 4.0 in vP6.1mut (p=0.0381; Fig. 
4.5B). We concluded, therefore, that the increase in tumor dissemination observed in 
vP6.1mut-infected animals supports a previous interpretation of vTR mediating 
integrin αV upregulation and increased metastasis (32).   
vTR and vTR P6.1 efficiently interact with RPL22. As previously reported, 
transformation mediated by EBER-1 is dependent on its interaction with RPL22 (12).  
In order to determine if wild-type and/or mutant P6.1 vTR interact with RPL22, we 
performed biotin-RNA pull-down assays.  vTR, vTR P6.1, chTR and EBER-1 were 
found to precipitate RPL22, while biotin-labeled β-actin control RNA did not (Fig. 
4.5C).  EBER-1 showed the strongest interaction, most likely because it contains 
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Figure 4.5. Disruption of vTR-TERT interaction leads to increased tumor 
dissemination and enhances interaction with RPL22. A) Dissemination pattern of 
vP6.1mut (22 chickens) and vP6.1rev (20 chickens) for in vivo experiment 2. 
Moribund chickens were euthanized, necropsied and evaluated for lymphoma 
dissemination. Results are shown as percentage of animals with 1-2, 3-4 or 5-6 organs 
containing lymphomatous lesions. B) Mean number of organs with gross tumors per 
animal with standard deviations. The mean number was significantly increased in the 
P6.1mut group indicated by the asterisk (p=0.0381). C) Biotin-RNA pull-down assay. 
Precipitated RPL22 (upper panel), unbound supernatant (middle panel), and RNA 
input control (lower panel) of indicated RNAs are shown.  The figure is a 
representative of three independent experiments yielding similar results.  
106 
 
 
 
 
 
 
107 
three independent RPL22 binding sites (8).  Enhanced interaction of vTR P6.1 was 
observed when compared to wild-type vTR and chTR. This could be caused by the 
conformational change of the adjacent P6 stem–loop structure, that exhibits high 
similarity to the EBER-1 stem-loop 3 that is known to interact with RPL22 
(unpublished data).  In addition, the abrogation of vTR-TERT interaction could 
increase the amount of free vTR available for RPL22 interaction, thereby providing an 
explanation for the increased number of solid tumors found in vP6.1mut infected 
animals.   
 
4.5. Overall Conclusion 
In this report, we demonstrate that the herpesvirus telomerase RNA, vTR, has at 
least two functions in virus-induced lymphomagenesis. One of its functions is 
dependent on vTR-TERT interaction, while the other is independent of the formation 
of an active telomerase complex. The rapid onset of lymphoma formation seems 
dependent on vTR-mediated telomerase activity because a delay in the development of 
tumors was observed when vTR-TERT interaction was abrogated. The documented 
increase in telomerase activity mediated by the presence of vTR in complex with 
TERT when compared to the presence of cellular TR likely plays an important role in 
the initial establishment and maintenance of MDV-transformed cells.  It may, 
therefore, facilitate the development of lymphomas by increasing the pool of candidate 
tumor stem cells. Functions of vTR that are independent of telomerase activity, 
however, are needed later in the process and influence homing of tumor cells to 
various organs, seeding and metastasis. These processes are likely a consequence of 
TR-mediated gene regulation shown by Le and coworkers (20). In addition, interaction 
of vTR with RPL22 suggests an alternative mechanism involved in transformation, as 
demonstrated for EBV EBER-1.  In conclusion, this study demonstrates that TR is 
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directly involved in tumor formation in vivo, in a fashion that is independent of its 
function as an integral component of an active telomerase complex. 
 
4.6. Material and Methods 
Cells and viruses. CECs were prepared from specific-pathogen-free embryos and 
maintained as described previously (23). Recombinant viruses were reconstituted in 
CECs by CaPO4 transfection of purified BAC DNA as described previously (14, 26). 
The lox-P-flanked mini-F sequences within the infectious clones were removed by 
cotransfection with a Cre recombinase expression vector (pCAGGS-NLS/Cre) (14). 
Removal of the mini-F sequences was ensured by analyzing recombinant virus stocks 
by analytic PCR as described previously (14). Virus propagation as well as 
determination of virus growth kinetics and plaque sizes were performed as described 
previously (27). 
Generation of mutant MDV. pP6.1mut and pP6.1rev were generated by two-
step Red-mediated recombination (14, 30). Primers used for the mutagenesis are given 
in Table 4.1.  
In vivo experiments. SPF P2a (MHC: B19B19) chickens were inoculated intra-
abdominally with 500 to 2,000 plaque-forming units at day 1 of age and housed in 
isolation units. All experimental procedures were conducted in compliance with 
approved Institutional Animal Care and Use Committee (IACUC) protocols (internal 
approval number: 2002-0085). Chickens were evaluated for symptoms of MDV-
induced disease on a daily basis and examined for gross tumors when clinical 
symptoms were evident.  
DNA extraction and qPCR assays. DNA was extracted from whole blood and 
MDV genomic copies were determined by qPCR (13, 15). Briefly, MDV DNA copy  
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Table 4.1. Primers used for cloning and mutagenesis. Underlined sequences 
indicate restriction enzyme sites. Bold indicates mutated sequences. 
ACGCGTGGCGGGTGGAAGfor
pcDNA-chTR
GCGTGTGGGAGCGACGCCrev
GCCGCCATGGCGCCCGTfor
pcDNA-RPL22
GTCCTCCTCCTCCTCCTCCTCCrev
ACGCGTGGCGGGTGGAAGfor
pcDNA-chTERT-His
GCGTGTGGGAGCGACGCCrev
TATAACGGAGGTATTGATGGTACTGTCfor
puc119-vTR-AU5
TATATAACACAGCGGAGCCTTCCACrev
GATCGCGGCGGCAATGGCrev
TCTTCGCCTCTGTCAGCCTCGfor
puc119-vTR-P6.1
GATCCTCTAGATGCGCATGTGGGAGCGACGCCrev
CATGCCTGCAGTAATACGACTCACTATAGGGACACGTGGCGGGTGGAAGGfor
puc119-vTR
CCGCATCTCCCGGGCGCCGCCGAGGCTGACAGAGGCGAACTCTTCGCGG
CGGCAATGGCGGGGCCAGTGTTACAACCAATTAACCrev
GCAGGCCGCGGTCGGCCGGCACCCGCCATTGCCGCCGCGAAGAGTTCGC
CTCTGTCAGCCTCGTAGGGATAACAGGGTAATCGATTTfor
pP6.1rev 
GCCGCATCTCCCGGGCGCCGCCGAGGCTGACAGAGGCGAAGAGATCGCG
GCGGCAATGGCGGGGCCAGTGTTACAACCAATTAACCrev
CGCAGGCCGCGGTCGGCCGGCACCCGCCATTGCCGCCGCGATCTCTTCG
CCTCTGTCAGCCTCGTAGGGATAACAGGGTAATCGATTTfor
pP6.1mut 
sequence (5' → 3')Construct name
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numbers were detected using primers and probe specific for the ICP4 locus and 
normalization was achieved using chicken inducible nitric oxide synthase (iNOS) 
genome copies. 
Cloning of vTR variants, chTERT, chTR and RPL22.. vTR was amplified 
from pRB-1B and subsequently cloned into the PstI and XbaI sites of the pUC119 
plasmid resulting in plasmid pUC119-vTR. The T7 promoter was inserted at the 5′ end 
of vTR via a 5′ overhang in the vTR-T7-for primer. Mutation of the template (AU5) 
and the P6.1 stem-loop was done based on pUC119-vTR by Phusion Site-Directed 
Mutagenesis (Finnzymes Inc.) according to the supplier’s instructions and resulting in 
pUC119-vTR-AU5 and pUC119-vTR-P6.1, respectively. Chicken TERT (chTERT) 
was obtained as a synthetic, codon-optimized sequence from GenScript (Piscataway, 
NJ USA), PCR amplified including the Kozak sequence and inserted into 
pcDNA3.1/V5-His TOPO (Invitrogen) containing a 5′ T7 promoter, resulting in 
plasmid pcDNA-chTERT-His. Chicken TR (chTR) and RPL22 was amplified from 
chicken DNA and inserted into pcDNA3.1/V5-His TOPO, resulting in pcDNA-chTR 
and pcDNA-RPL22-His. Oligonucleotides used for amplification are given in Table 
4.1.  
In vitro transcription. vTR variants, chTR, EBER-1, or β-actin were transcribed 
using the Maxiscript T7 kit (Ambion) following the manufacturer’s instructions where 
the linearized plasmids pUC119-vTR, pUC119-vTR-AU5, pUC119-vTR-P6.1, 
cDNA-chTR, pSG5-EBER-1 (a kind gift of Dr. Rona Scott, Louisiana State 
University Health Science Center, Shreveport, LA) and pTRI-β-actin (Ambion) served 
as templates.  Biotin-labeled RNAs were generated using the biotin RNA labeling mix 
(Roche).  chTERT and RPL22 were transcribed via the mMESSAGE mMACHINE® 
T7 Kit (Ambion) according to the supplier’s recommendation using linearized 
pcDNA-chTERT-His or pcDNA-RPL22 as templates. RNAs were purified via the 
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RNeasy Kit (Qiagen), analyzed on a 2% denaturing agarose-formaldehyde gel, and 
quantified with a NanoDrop 1000 (Thermo Scientific).  
In vitro translation of chTERT. In vitro transcribed chTERT-His or RPL22-His 
RNA was used for in vitro translation using the Rabbit Reticulocyte Lysate System 
(Promega) according to the manufacturer’s protocol. chTERT-His and RPL22-His 
expression was analyzed by Western blotting, using a mouse anti-5хHis antibody 
(Qiagen). 
TRAP assay. In vitro-transcribed vTR variants (1 µg) were incubated with 1 µL 
of in vitro translated chTERT, as shown in Figure 4.1C, for 1 h at 30 °C to reconstitute 
the telomerase complex. Telomerase activity was subsequently determined using the 
TRAPeze gel-based telomerase detection kit S7700 (Chemicon) following the 
manufacturer’s instructions.  
Biotin-RNA pull-down assay. Four µL in vitro translated RPL22-His was mixed 
with 3 nmol biotin labeled vTR, vTR P6.1, chTR, EBER-1 or β-actin control RNA and 
incubated in binding buffer (150 mM NaCl, 50 mM Tris pH 7.0, 0.1% Tween20, 1 µg 
of tRNA, 0.5 mM DTT, 0.5 mM PMSF) containing 10 µg tRNA  for 1h at 37°C. 20 
uL EZview Strepavidin beads (Sigma) were washed with binding buffer and added to 
the setup. After binding occurred for 1 h at RT, supernatant was collected and beads 
washed 7 times with binding buffer containing 1 µg tRNA. Precipitated and unbound 
protein was analyzed by Western blotting, using a mouse anti-5хHis antibody 
(Qiagen).  
Statistical analysis. Significant differences in MD incidence were determined 
using the Wilcoxon rank-sum test (Fig. 4.4C). Significant differences in tumor 
distribution were determined using Chi-Square test (Fig. 4.5A). Significant differences 
in mean tumor incidences were determined using Student's t test (Fig. 4.5B). 
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5.1. Abstract 
Several lymphotropic herpesviruses, including Epstein Barr virus (EBV), human 
herpesvirus 6 (HHV-6) and Marek’s disease virus (MDV), are capable of integrating 
their genomes into host chromosomes.  For the latter two viruses, integration of viral 
DNA is found at the distal end of host chromosomes, where telomeres consisting of 
telomeric repeat sequences and telomere associated proteins form structures that 
prevent chromosomal instability and degeneration.  It is also known that HHV-6, 
MDV and other herpesviruses harbor telomeric repeats identical to host telomeric 
sequences at either end of the linear viral genomes, but the role of these genetic 
elements has remained enigmatic.  Using MDV as a natural virus-host model, we 
show that herpesvirus telomeric repeats facilitate viral genome integration into host 
telomeres and that these repeat structures are crucial for efficient tumor formation and 
reactivation of latent virus from the quiescent state of infection.  Our results, therefore, 
provide the first conclusive evidence that herpesvirus telomeric repeats mediate 
chromosomal integration.  Finally, our data and the fact that telomeric repeats are 
present in many herpesvirus species suggest that telomere-mediated integration is a 
highly conserved mechanism, which ensures faithful virus genome maintenance in 
host cells during cell division and also allows efficient mobilization of dormant viral 
genomes. This mobilization mechanism, therefore, appears to endow herpesviruses 
with the ability to spread within a population of susceptible individuals and thus is 
necessary for continued virus evolution and survival.   
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5.2. Introduction 
A number of DNA viruses and retroviruses are capable of integrating their genetic 
material into the host genome, which ensures viral genome maintenance and 
replication during cell division.  Among the herpesviruses that are found in animals as 
diverse as crustaceans and humans, Epstein-Barr virus (EBV), human herpesvirus 6 
(HHV-6), and Marek’s disease virus (MDV) have been found in an integrated state 
during the latent, quiescent stage of the virus life cycle (6, 8, 9, 19).  Other members 
of this group of viruses maintain their genomes exclusively as an episome during this 
phase of infection. Establishment of latency is a unifying and important principle for 
all herpesviruses that is utilized for prolonged, usually life-long, maintenance of the 
agents’ genetic material in once infected hosts.  From the latent state, virus is 
reactivated intermittently to allow virus spread from infected to uninfected individuals 
in a population (14).  Latency is a poorly understood series of events, which will 
uniformly result in the expression of only very few viral genes with the sole purpose 
of genome maintenance whilst avoiding a fully lytic replicative cycle causing cellular 
death. Latency may only require genome maintenance when non proliferative cells 
such as neurons are infected. However, in other cell types, for example lymphocytes, 
faithful and continued replication of viral DNA during each mitosis must be ensured 
(29).   
Herpesvirus integration is well-known for maintenance of viral DNA in rapidly 
dividing cells, but the mechanistic principles underlying this process have remained 
elusive.  Previously, HHV-6 and MDV, two lymphotropic viruses that can cause 
lymphoma, have been found integrated at the distal ends of host chromosomes (1, 7, 
18).  A recent study suggested HHV-6 integrates at the proximal end of telomeres, 
protein-associated repeat sequences that protect chromosomes from damage and 
extensive shortening during DNA replication, and that integration in telomeres 
119 
facilitates vertical transmission of the virus (1).  In addition HHV-6A and B, human 
herpesvirus 7 (HHV-7), MDV and several other herpesviruses harbor telomeric 
repeats (TMRs) identical to host telomere sequences (TTAGGG)n at either end of their 
linear genomes (15, 28).  Based on the observations of the presence of telomeric 
repeats in viral genomes and their integration into host telomeres, we hypothesized 
that herpesviruses use these virus-specific telomeric repeat sequences to integrate their 
genetic information into host telomeres, thereby ensuring faithful replication and 
maintenance of the viral genome in rapidly dividing cells. 
In the case of MDV, integration and efficient induction of the latent state of 
infection is considered the basis for tumor formation. The efficiency of establishing 
latency has been shown to correlate directly with the number of cells harboring latent 
genomes.  Out of many latently infected and initially transformed cells, one 
outcompetes all others with the consequence that tumours within one animal are 
almost invariably monoclonal (6, 7). The establishment of MDV latency results in the 
expression of proteins and RNAs that play a crucial role in the maintenance of the 
quiescent stage, but also survival of the host cell.  Arguably the most important 
latency- and tumor-associated MDV gene is Meq, which serves as a repressor of lytic 
viral gene products, but at the same time is a potent transcriptional activator of the 
proto-oncoprotein c-Jun and interacts with p53 as well as Rb. Meq thereby strongly 
enhances transformation and T cell proliferation, which leads to a rapid onset of tumor 
formation (2, 16, 17, 21) , making MDV an optimal natural virus-host model for 
studying herpesvirus integration and the effects on tumorigenesis. 
Here we show that herpesvirus telomeric repeats facilitate directed integration 
into host telomeres, which is crucial for efficient tumor formation and virus 
reactivation from latency. In the absence of the viral telomeric repeats, herpesvirus 
integration is severely impaired and occurs at random, single sites within 
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chromosomes in the form of concatemers. Our observation that genome integration 
occurs even in the absence of telomere-mediated integration suggests that herpesvirus 
integration is a prerequisite for transformation and tumorigenesis as well as 
reactivation and spread to susceptible hosts. 
 
5.3. Results and Discussion 
MDV integrates into host telomeres. MDV is a highly oncogenic animal 
herpesvirus (21) that is able to integrate its genome at the distal ends of multiple 
chromosomes (7).  To elucidate whether MDV integrates into host telomeres during 
the latent and tumor phase of infection, we performed pulsed field gel electrophoresis 
experiments.  DNA from MDV-induced lymphoblastoid T cell lines (LCLs) was 
fragmented with BclI, a restriction enzyme frequently cutting in both the host and viral 
genome, but not in telomeric repeats (Fig. 5.1A). Southern blot analysis using probes 
specific for the terminal fragment of the TRS of the viral genome revealed that MDV 
is integrated into large fragments of up to 450 Kbp that were indigestible with BclI. 
The sizes of the reactive fragments were found to correlate well with that reported for 
chicken telomeres, which range in size between 10 and 2,000 kbp (Fig. 5.1B) (5). The 
presence of telomere sequences in fragments containing the viral genome was 
confirmed using a telomere specific probe (TMR), which demonstrated that fragments 
reactive with the short repeat region of the genome (TRS, Fig. 5.2A) coincided with 
bands positive for telomeres (Fig. 5.1B). These results suggest that MDV integrates 
into or in very close proximity of the telomeres.  To further define where exactly 
MDV integrates into the chromosome, we probed for sequences specific for the other 
terminal genome region, the terminal repeat long sequences (TRL, Fig. 5.2A).  
Hybridization with TRL sequences resulted in very short reactive fragments, indicating 
that MDV indeed integrates into telomeric sequences, which are located at either 
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Figure 5.1. Identification of MDV integration sites. A) Schematic representation of 
potential integration sites of the MDV genome within the host chromosome. 
Fragments resulting from digestion with BclI are depicted and expected fragment sizes 
are given. Terminal MDV genome fragments (red bars), telomeres and BclI restriction 
sites are indicated. B) Pulsed field gel electrophoresis (PFGE) analysis of LCLs using 
BclI. PFGE patterns of three representative cell lines analyzed by Southern blot, 
probing for the left MDV terminus (TRL), right MDV terminus (TRS) or telomere 
sequences (TMR) are shown.  The 22.4 and 27.0 kbp fragments correspond to 
uncleaved termini and internal repeat fragments of the viral DNA. Arrows indicate 
colocalization of fragments that contain the TRS and high molecular weight telomere 
sequences. Results are representative of three independent experiments giving 
identical results.  The number of integration sites detected by FISH is given at the 
bottom of the blot images. 
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the proximal (subtelomeric) or distal end of the telomeres (Fig. 5.1B).  Our results for 
lymphotropic MDV, therefore, are in agreement with a recent report showing that 
integration of a human lymphotropic herpesvirus, HHV-6, occurs at the internal end of 
the telomeres (1).  
Integrity of viral telomeric repeats is dispensable for virus growth in vitro. 
MDV DNA replication results in the formation of four isomers, where its two unique 
regions (UL and US) can invert relative to the long or short inverted repeat sequences 
(TRL and TRS).  MDV DNA harbors an additional copy of telomeric repeats that 
ensures the presence of telomeres at all possible termini of the four DNA isomers (Fig. 
5.2A).  To address the question of whether the viral telomeric repeats mediate 
integration and if integration is important for establishment of latency and oncogenesis 
of MDV, we replaced the repeats present in pRB-1B, an infectious BAC clone of the 
highly oncogenic RB-1B MDV strain, with either structurally similar repeats 
harboring only two nucleotide exchanges (pTE1) relative to the telomere sequences or 
with completely scrambled repeats (pTE2) (Fig. 5.3).  We replaced both the terminal 
and internal telomeric repeat regions that each contain multiple telomeric repeats 
(mTMR), with up to 100 copies of telomeric repeats, and short telomeric repeats 
(sTMR), which constantly specify 6 copies (Fig. 5.3).  In an additional mutant, we 
deleted the multiple telomeric repeat region (p∆mTMR) to define the role of the 
longer repeats (Fig. 5.3).  Based on the pTE1, pTE2 and p∆mTMR mutants, we also 
engineered revertant infectious clones in which the original telomere sequences were 
restored in both loci (pTE1rev, pTE2rev and p∆mTMRrev).  All infectious clones 
were confirmed by PCR, DNA sequencing and multiple restriction fragment length  
polymorphism analyses (RFLP) to ensure the integrity of the genome and to exclude 
fortuitous mutations elsewhere in the genome.  Southern blot analysis confirmed that 
the herpesvirus telomeric repeats and restored telomeres were as designed in the 
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Figure 5.2. MDV genomic isomers. Schematic representation of the four isomeric 
forms of the MDV genome. A) Orientation of the unique-long (UL) and unique-short 
(US) segments of the genome is shown relative to each other and the internal and 
terminal repeat regions of the long (TRL, IRL) and short segment (IRS, TRS). 
Telomeric repeats (TMR) within the genome are indicated. B) Southern blot analysis 
of the TE1 mutant viral genome and revertant genomes. Fragments containing 
telomeric repeats or the TE1 repeat were detected with specific oligonucleotide probes 
[TMR: (TTAGGG)7 or TE1 (TAAGGC)7] in parental pRB-1B, recombination 
intermediates and final mutant clones. 
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Figure 5.3. MDV telomeric repeat mutants. Schematic representation of the MDV 
genome with a focus on viral a-like sequences containing the multiple (mTMR) and 
short telomeric repeat region (sTMR) present in the MDV genome. Recombinant BAC 
constructs in which the telomeric repeats (TTAGGG)n were replaced by TE1 
(TAAGGC)n or TE2 (ACGACA)n as well as a BAC construct in which the mTMR 
region was deleted are shown.  
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recombinant viral genomes (Fig. 5.2B). Recombinant viruses were reconstituted from 
BAC DNA in chicken embryo cells, and growth properties were evaluated using 
multi-step growth kinetics (data not shown) and plaque size assays.  The viruses 
derived from pTE1 (vTE1), pTE2 (vTE2) and p∆mTMR (v∆mTMR) showed growth 
properties that were virtually indistinguishable from those of parental or revertant 
viruses (Fig. 5.4A-C), indicating that neither the telomeric repeat sequences nor the 
mTMRs are important for lytic replication in vitro.   
 
 
 
 
Figure 5.4. Mutation of herpesvirus telomeric repeats has no effect on virus 
replication in vitro. A-C), Plaque size assay of vRB-1B, vTE1 and vTE1rev (A), vTE2 
and vTE2rev (B) and v∆mTMR and v∆mTMRrev (C).  Plaque areas were determined 
for 50 randomly selected plaques of each virus.  Results are shown as mean plaque 
areas in percent of the parental vRB-1B with standard deviations (error bars). 
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Absence of herpesvirus telomeric repeats significantly reduces disease 
incidence and tumor development. To address the role of the herpesvirus telomeric 
repeats in disease and tumor development in vivo, one-day old P2a chickens highly 
susceptibe to MDV infection were experimentally infected with parental vRB-1B, 
mutant vTE1, vTE2, or v∆TMR viruses, or the respective revertant viruses.  After 
infection, we monitored viral levels in peripheral blood as well as disease and tumor 
development.  Viral loads in the blood were only mildly affected in animals infected 
with vTE1, vTE2 or v∆mTMR (Fig. 5.5A-C), indicating that herpesvirus telomeric 
repeats do not play a prominent role in lytic replication in vivo, similar to the situation 
in cultured cells.  In stark contrast, disease and tumor development were severely 
impaired in the telomere mutant viruses.  Only 57.1%, 47.1% and 57.9% of chickens, 
infected with vTE1, vTE2 or v∆mTMR, respectively, developed clinical disease, 
while 95-100% of animals infected with either parental or revertant viruses presented 
with clinical disease (Fig. 5.5D-F).  Tumor development was also significantly 
decreased in animals infected with vTE1 (65.7%, p=0.021), vTE2 (48.6%) and 
v∆mTMR (61.4%, p=1.98х10-6) when compared to parental vRB-1B or repair viruses 
(95-100%) (Fig. 5.5G-I). Taken together, the average tumor incidence of all telomere 
mutants viruses (vMut) (60.0%) in 9 independent experiments was significantly 
reduced when compared to parental vRB-1B (97.5%; p=1.26х10-8) or revertant viruses 
(vRev) (98%; p=3.68х10-6). 
In order to determine if mutation of the telomeric repeats affected spread to 
naïve hosts within a population, we housed infected and uninfected chickens together.   
While mutant viruses were fully able to spread to uninfected animals as evidenced by 
qPCR detection of viral DNA in chicken blood (data not shown), disease incidence in 
animals infected with vTE1 (11.1%), vTE2 (25.0%) or v∆mTMR (33.3%)  
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Figure 5.5. Mutation of herpesvirus telomeric repeats mildly affects lytic replication, 
but severely impairs disease and tumor development in vivo. A-C), qPCR analysis of 
the viral genome copies (ICP4) relative to host genome copoies (iNOS). Blood 
samples of animals infected with vRB-1B, vTE1 or vTE1rev (A), vTE2 or vTE2rev 
(B), and v∆mTMR or v∆mTMRrev (C) were taken at 4, 7, 10, 14, 21, and 28 dpi, and 
total DNA was extracted.  Mean MDV genome copies per 1 x 106 genome copies of 
eight infected chickens per group are shown with standard deviations (error bars). D-
F), MD incidence in percent of chickens infected by the intra-abdominal route with 
vRB-1B (D, n=5; E, n=19; F, n=19), vTE1 (n=7) or vTE1rev (n=8) (D), vTE2 (n=17) 
or vTE2rev (n=20) (E), and v∆mTMR (n=19) or v∆mTMRrev (n=20) (F) was 
monitored during the indicated time period after infection. G-I), Tumor incidence in 
P2a chickens infected with parental vRB-1B or mutant viruses, (G) vTE1 and 
vTE1rev; (H) vTE2 and vTE2rev, and (I) v∆mTMR and v∆mTMRrev. Results are 
shown as mean tumor incidences for two (G), three (H) or four (I) independent 
experiments  with standard deviations (error bars). The mean tumor incidences in 
chickens infected with vTE1 and v∆mTMR were significantly decreased compared to 
those infected with vRB-1B and are indicated by asterisks (G, p=0.021; I, p=1.98x   
10-6). Each group contained between 5 and 20 animals with an average group size of 
n=13.6. 
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was dramatically diminished when compared to parental or revertant viruses (80-
100%) (Fig. 5.6A-C). Tumor development was also significantly decreased in 
chickens infected with vTE1 (25.5%), vTE2 (25.0%) or v∆mTMR (27.8%, p=0.01) 
when compared to those infected with parental vRB-1B or repair viruses (83.8-100%) 
(Fig. 5.6D-F). Average tumor incidence was significantly reduced after infection with 
telomere mutant viruses (vMut) (26.3%) in 7 independent experiments when 
compared to parental vRB-1B (96.8%; p=2.17x10-7) or revertant viruses (vRev) 
(86.6%; p=7.72x10-5).   
 
Figure 5.6. Disease and tumor development are severely impaired in absence of the 
viral telomeric repeats in animals infected via the natural route of infection. A-C), MD 
incidence in percent determined for in-contact animals housed with chickens infected 
with vRB-1B (n=9), vTE1 (n=10) or vTE1rev (n=10) (A), vTE2 (n=8) or vTE2rev 
(n=9) (B), and v∆mTMR (n=8) or v∆mTMRrev (n=8) (C). Chickens were monitored 
during the indicated time period and MD was recorded after necropsy and gross 
pathological examination. D-E), MD incidence in percent of contact animals housed 
with animals infected with vRB-1B or mutant viruses. (D) vTE1 and vTE1rev; (E) 
vTE2 and vTE2rev, and (F) v∆mTMR and v∆mTMRrev. Results are shown as mean 
tumor incidences of two (D, E) or three independent experiments (F) with standard 
deviations (error bars). The mean tumor incidences in chickens infected with 
v∆mTMR in F were significantly decreased compared to incidences in animals 
infected with vRB-1B and are indicated by asterisks (p=0.011). Each group contained 
between 2 and 10 animals with an average group size of n=6.7. 
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The results suggested an even more drastic defect in tumor development of 
vTE1, vTE2 and v∆mTMR in chickens exposed by the natural route of infection.  To 
confirm that the defect in disease and tumor development was not only restricted to 
chickens that are highly susceptible to MDV, we also infected N2a chickens, which 
exhibit increased resistance to MDV infection.  Similar to the situation in P2a animals, 
tumor incidences were drastically reduced after infection of N2a chickens with vTE1 
(25.6%), vTE2 (15.8%) or v∆mTMR (15.8%) when compared to the incidence after 
infection with the corresponding revertant viruses (42.9 – 63.1%) (Fig. 5.7A-C).    
 
 
 
Figure 5.7. Tumor development is severely impaired in the absence of viral telomeric 
repeats in chickens with increased resistance to MDV infection.  A-C), Tumor 
incidence in resistant N2a chickens infected with parental vRB-1B or mutant viruses,   
(A) vTE1 and vTE1rev; (B) vTE2 and vTE2rev, and (C) v∆mTMR and v∆mTMRrev.  
Results are shown as mean tumor incidences of one (B,C) or two (A) independent 
experiments with standard deviations (error bars). Each group contained between 18 
and 21 animals with an average group size of n=19.5. 
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Integration defects of viruses harboring mutant telomeric repeats. We then 
asked whether the telomere mutant viruses were still able to integrate viral DNA into 
the host genome and performed metaphase fluorescent in situ hybridization (FISH).  
Analysis of LCLs derived from animals infected with parental vRB-1B, mutant or 
revertant viruses revealed that vTE1, vTE2 and v∆mTMR had severe integration 
defects.  While integration of wild-type MDV DNA was identified in the telomeres of 
up to 15 different chromosomes in individual LCLs derived from chickens infected 
with vRB-1B or revertant viruses, vTE1, vTE2 and v∆mTMR DNA was found 
integrated invariably in only a single chromosomal locus of each cell line (Fig. 5.8A 
and B).   
We then applied PFGE and Southern blot analyses to confirm whether 
integration of wild-type MDV DNA as detected by FISH truly represents integration 
or rather tethering of the viral episome to host chromosomes as was shown for EBV 
(27) and to investigate the status of viral DNA after integration of viruses with mutant 
telomeric repeats.  Digestion with SfiI, a restriction enzyme that does not cut within 
the MDV genome, allowed the distinction between integrated and non-
integrated/tethered MDV DNA (Fig. 5.9A).  Extended proteinase K digestion of LCL 
DNA embedded in agarose was applied to exclude the possibility of tethering of the 
viral genome to the host chromosome by a proteinaceous structure.  Consistent with 
the FISH results, multiple integration sites with varying sizes of reactive fragments 
were identified in DNA of LCLs from animals infected with vRB-1B or vTE1rev.  In 
contrast, in the case of LCLs derived from vTE1-infected animals, integration was 
restricted to a single large DNA fragment of approximately 1.9 Mbp in size.  To 
address whether the integration sites found in vTE1 LCLs also mapped to telomeres, 
we performed PFGE after BclI digestion.  Southern blotting confirmed that vTE1 
genomes were only detected in low molecular weight fragments of 4-20 kbp in size  
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Figure 5.8. Integration is severely impaired in absence of the viral telomeric repeats. 
A) Fluorescent in situ hybridization (FISH) analysis detecting MDV integration sites 
(anti-DIG FITC, green) in metaphase chromosomes (DAPI stain, blue) of 
representative cell lines of vRB-1B, vTE1, vTE2 and v∆mTMR. B) Average number 
of integration sites in vRB-1B, mutant and revertant cell lines. The number of 
analyzed cell lines and the frequencies of integration events are given.  
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with both the TRS and TRL probe.  We did not detect, however, any colocalization 
with telomere-containing fragments (Fig. 5.9B, Fig. 5.10A-C). This data demonstrated 
that only minimal changes in MDV telomeric repeat sequences abrogated specific 
integration into host telomeres and suggests that mutant viral DNA integrates 
randomly into intrachromosomal sites.  
In a following series of experiments we determined if MDV integrates as a 
single viral genome or as concatemers and analyzed MDV genome copy numbers in 
LCL’s.  Large genome fragments with high intensity of reactive bands (Fig. 5.9A) had 
already suggested that vTE1 might be integrated not as a single copy but as multiples 
in the form of head-to-head or head-to-tail concatemers.  Viral copy numbers in LCLs 
were determined by Southern blot analysis using normalization to copies of host β2 
microglobulin (B2M, Fig. 5.10A-D).  Although integrated at only one site, MDV 
genome copy numbers in all vTE1 cell lines analyzed were comparable to those 
present in CU482, a cell line with 11 integration sites, clearly indicating that vTE1 
genomes were integrated as concatemers (Fig. 5.9C, Fig. 5.10E). These findings were 
also confirmed by qPCR analysis of numbers of viral DNA copies individual LCLs 
(data not shown).   
Reactivation of viruses with mutant telomeric repeats is severely 
impaired. Finally, we asked whether integration of viral genomes into telomeres had a 
measurable effect on virus fitness, more specifically we assessed reactivation of virus 
from the latent, quiescent state of infection. While genome maintenance during the 
latent phase of the virus life cycle is an important transitory phase, reactivation and 
spread to new hosts are essential for continued virus survival.  Since integration into 
host telomeres could allow virus genome mobilization through homologous 
recombination between virus and host telomeres, we analyzed the efficiency of virus 
reactivation from LCLs.  Reactivation assays that rely on induction of the lytic  
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Figure 5.9. Integration occurs randomly in the absence of viral telomeric repeats. A) 
Schematic representation and corresponding PFGE and Southern blot analysis of LCL 
DNA digested with SfiI. Fragment sizes generated by SfiI digestion of integrated and 
non-integrated MDV genomes are depicted and sizes are given.  The size of the linear 
MDV genome observed during lytic replication is indicated by an arrow.  Results are 
representative of three independent Southern blot analyses. B) Southern blot of DNA 
of LCLs derived from animals infected with vTE1 and digested with BclI. Potential 
intragenomic and telomeric integration sites are indicated. Results are representative 
of three independent Southern blot analyses. C) Quantification of MDV copies in 
tumor cells.  Results are shown as mean herpesvirus genome copies detected by the 
TRL probe relative to B2M in three independent experiments. The data are shown 
relative to LCL CU482 derived from a vRB-1B-infected chicken with standard 
deviations (error bars). 
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Figure 5.10. Herpesvirus telomere mutants integrate as concatemers into 
chromosomes. A-D) Pulsed field gel electrophoresis (PFGE) and Southern blot 
analysis of DNA of LCLs derived from chickens infected with vRB-1B, vTE1 or 
vTE1rev.  DNA was digested with BclI and fragments containing the left terminus 
(TRL, A), right terminus (TRS ,B), telomere sequences (TMR, C) or β2 microglobulin 
(B2M, D) were detected using sequence-specific DIG-labeled probes. Results are 
representative for three independent experiments.  E) Quantification of MDV copies in 
tumor cells. Results are shown as mean herpesvirus genome copies detected by the 
TRS probe relative to B2M in three independent experiments. The data are shown 
relative to LCL CU482 derived from a vRB-1B-infected chicken with standard 
deviations (error bars).    
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replication cycle from latent genomes revealed that vTE1, vTE2 and v∆mTMR were 
severely impaired with respect to their efficiency of genome mobilization and 
reactivation from latently infected cells (Fig. 5.11A-C). The average number of 
plaques induced on CEC’s per 1x106 tumor cells was significantly (5- to 39-fold) 
decreased in the case of cell lines derived from birds infected with vTE1 (1.13 x 104), 
vTE2 (7.06 x 104) and v∆mTMR (0.91 x 104) when compared to those from birds 
infected with parental vRB-1B (3.53 x 105) (Fig. 5.11A-C).  We concluded that 
integration of MDV DNA into host telomeres serves a purpose beyond genome 
maintenance during latency by allowing efficient and rapid mobilization of virus 
genomes in response to external cues for initiation of the lytic phase of infection.   
In summary, we conclude from our results that telomere-mediated integration 
plays a critical role in the establishment of the latent state and tumorigenesis of MDV 
on the one hand, and mobilization of latent genomes required for virus reactivation 
and spread to other individuals in a population on the other hand (Fig. 5.12).  
Therefore, our data proves that integration of herpesvirus DNA is not, as had been 
speculated earlier, a dead-end, but an integral part of the virus’ life cycle. 
 
5.4. Material and Methods 
Cells and viruses. Chicken embryo cells (CEC) were prepared from specific-
pathogen-free (SPF) embryos and maintained as described previously (20). 
Recombinant viruses were reconstituted in CEC by CaPO4 transfection of purified 
bacterial artificial chromosome (BAC) DNA as described previously (12, 25). The 
mini-F sequences flanked by loxP sites within the infectious clones were removed by 
co-transfection with a Cre recombinase expression vector (pCAGGS-NLS/Cre) (12). 
Removal of mini-F sequences was ensured by analyzing recombinant virus stocks via  
PCR as described previously (12). Virus propagation as well as determination of virus 
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Figure 5.11. Reactivation is significantly impaired in the absence of viral telomeric 
repeats. A-C) Reactivation assay using LCL’s derived from animals infected with 
vRB-1B, vTE1 or vTE1rev (A), vTE2 or vTE2rev (B), or v∆mTMR or v∆mTMRrev 
(C). Representative images of virus reactivation in chicken embryo cells are shown. 
Quantification of reactivation assays is shown as average number of plaques per 1 x 
106 tumor cells for each individual cell line (A-C, right panel), performed in triplicate 
for each of three independent experiments. Reactivation of lytic virus from vTE1, 
vTE2 and v∆mTMR-derived LCLs was significantly reduced compared to that from 
vRB-1B-derived LCLs as indicated by the asterisks (A, p=0.013; B, p=0.039; C, 
p=0.025).  
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Figure 5.12. Model of herpesvirus genome integration and mobilization in presence 
and absence of viral telomeric repeats.  Integration of wild type virus into host 
telomeres is efficiently mediated by the herpesvirus telomeric repeats. It allows 
efficient tumorigenesis and reactivation from latency, while random integration events 
are rare. Telomere mutant viruses (vTE1, vTE2 and v∆mTMR) are not able to 
integrate into telomeres, but integrate at random sites within chromosomes in form of 
concatemers. This integration process is inefficient and results in significantly reduced 
tumorigenicity and reactivation of the virus. Reactivation from latency occurs very 
efficient in the presence and is severely impaired in the absence of the herpesvirus 
telomeric repeats. 
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 growth kinetics and plaque sizes were performed as described previously (26). 
Generation of mutant MDV. The MDV telomere region (Fig. 5.3) was amplified 
from pRB-1B and cloned into the pCR2.1 Topo vector (Invitrogen) resulting in 
pTMR.  Plasmids containing a synthetic telomere region in which viral telomeric 
repeats (TTAGGG)n were replaced by telomere exchange repeats 1 (TAAGGC)n or 
telomere exchange repeats 2 (ACGACA)n were obtained from Celtec and Genscript, 
respectively, and designated pTE1 and pTE2.  Transfer plasmids for mutagenesis were 
generated as described previously (30).  Briefly, the aphAI-I-SceI cassette was 
amplified from pEPkan-SII and inserted into pTMR, pTE1 or pTE2 using a unique 
SacI or NheI restriction site within the viral telomere region resulting in plasmids 
pTMR-transfer, pTE1-transfer and pTE2-transfer, respectively. Corresponding transfer 
plasmids and oligonucleotides (Table 5.1) were used for mutagenesis as described 
previously (30).  All clones were confirmed by PCR, DNA sequencing, Southern blot 
analysis and multiple restriction fragment length polymorphism analyses (RFLP) to 
ensure integrity of the genomes and to exclude fortuitous mutations elsewhere in the 
genome (data not shown).  Primers used for transfer plasmids and mutagenesis are 
given in Table 5.1. 
In vivo experiments. SPF P2a (MHC haplotype B19B19) or N2a (MHC haplotype 
B21B21) chickens were experimentally infected by intra-abdominal inoculation with 
500 to 2,000 plaque-forming units at day 1 of age or via the natural route of infection 
by co-housing of uninfected with infected animals. All experimental procedures were 
conducted in compliance with approved Institutional Animal Care and Use Committee 
(IACUC) protocols under the internal approval number 2002-0085.  Chickens were 
evaluated for symptoms of MDV-induced disease on a daily basis and examined for 
tumorous lesions when clinical symptoms were evident or at termination of the 
experiments. 
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Table 5.1. Oligonucleotides used for cloning, Southern blot probes and BAC 
mutagenesis.  
 
 
DNA extraction and qPCR analysis. DNA was extracted from whole chicken 
blood using the EZ 96 blood DNA kit (Omega Bio-Tek) and MDV genomic copies 
were determined by qPCR (11, 13).  MDV DNA copy numbers were detected using 
primers and probe specific for the ICP4 locus and normalization was achieved by 
determining copies of the chicken inducible nitric oxide synthase (iNOS) gene (12). 
Lymphoblastoid cell lines (LCLs). LCLs were generated as described previously 
(3, 4). Tumor tissue from MDV-infected animals was harvested and sieved through a 
cell strainer before lymphocytes were isolated using Histopaque 1119 (Sigma) density 
gradient centrifugation. Purified cells were cultivated in Leibovitz-McCoy medium as 
CCCGCCGATGCTGCCCTAAACfor
TRS probe
TCCGCCAGACACCTACTCAAGrev
TCCCTTCCCCTTTTACTTTGTTTGfor
TRL probe
TGCCGCCCCAACTGCTCATrev
GTATAAAAAAAAATTTCGTCGAACCCCTAGCGGCCAACCGATCCCCCCAAATTTTCACCCfor
∆mTMR
GGAGCAGGGATGTGGTCTACGAACCGGATGTAGTAGTGCAGGCAGGTGTACAACTGCrev
GCTTTGAGCTCGGGATCGAGACTAGGTTCACGGTAGGGATAACAGGGTAATCGATTTfor
pTMR-transfer
ATCCCGAGCTCAAAGCACGGAAATCCACACTGGAACCGCCAGTGTTACAACCAATTAACCrev
CTAAGGCTAGCGCTAAGGGTTCAGGCCTAGGCTAAGTAGGGATAACAGGGTAATCGATTTfor
pTE1-transfer
TAGCGCTAGCCTTAGCCTTAGGCCAGTGTTACAACCAATTAACCrev
GCTTTGAGCTCGGGATCGAGACTAGGTTCACGGTAGGGATAACAGGGTAATCGATTTfor
pTE2-transfer
ATCCCGAGCTCAAAGCACGGAAATCCACACTGGAACCGCCAGTGTTACAACCAATTAACCrev
CGCGCCCTCTAACCCTCTCGCGGCCACACACTGTATAAAAAAAAATTTCGTCGAACCfor
TE1, TE2 & Rev
GGAGCAGGGATGTGGTCTACGAACCGGATGTAGTAGTGCAGGCAGGTGTACAACTGCrev
CGGATGCTGGAGCTGCCfor
pTMR
CTGCGAGATGCGGGCTGrev
TGCGGCTCCTTCAGCGTCTCGTGfor
B2M probe
GAAGGCGGCGGCGGTGGTGrev
sequence (5' → 3')Construct name
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modified by Hahn (Cellgro) supplemented with 10% FBS and 5% chicken serum at 
41°C under a 5% CO2 atmosphere. 
Fluorescence in situ hybridization (FISH).  Metaphase chromosome 
preparations and FISH analysis were performed as described previously (23).  A 
digoxigenin (DIG)-labeled MDV whole genome probe was generated via the DIG 
High Prime kit (Roche) and used to detect MDV integration sites that were visualized 
using a FITC-conjugated anti-DIG antibody (Sigma). Metaphase FISH preparations 
were analyzed using the Axio Imager M1 system and the Axiovision software (Zeiss). 
Pulsed field gel electrophoresis (PFGE) analysis. PFGE analysis was performed 
as described previously (10).  LCLs (1 x 107/ml) were embedded in 1% agarose and 
digested at 50ºC for 48 h hours in lysis buffer (0.5 M EDTA, 1% (w/v) N-
laurylsarcosine) containing 1 mg/ml Proteinase K.  Proteinase K was inactivated with 
0.01 mM phenylmethanesulfonyl fluoride and agarose plugs digested with either SfiI 
or BclI (New England Biolabs) overnight according to manufacturer’s instructions.  
DNA fragments were resolved by PFGE using the CHEF-DR III system (Bio Rad).  
SfiI fragments were resolved with 50-100 s and BclI fragments with 1-25 s switch time 
gradients at 6V/cm, 14ºC, a 120º angle and run times of 36 h and 24 h, respectively.  
Southern blot analysis. Southern blots were performed after DNA transfer onto a 
positively charged nylon membrane (Whatman) (24). Fragments containing the TRL or 
TRS termini of the MDV genome were identified with specific probes generated via 
the PCR DIG Probe Synthesis kit (Roche).  Telomeric repeats or mutant repeats were 
detected using DIG-labeled oligonucleotide probes (MWG Eurofins, Table 5.1).  
Reactivation assay.  Established LCLs were purified via Histopaque 1119 
gradient centrifugation (Sigma) (22), washed with PBS, and serial 10-fold dilutions   
(1 x 103, 1 x 104, 1 x 105 or 1 x 106) LCLs were seeded on fresh CEC cultures. MDV 
reactivation was stimulated by co-cultivation of LCLs with CEC at low serum 
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concentrations (0.1% FBS) and a temperature shift to 37º C as described previously 
(4). LCLs were completely removed 24 h after seeding through extensive washing.  
Four days after infection, CEC cultures were fixed, stained and analyzed by 
immunofluorescence using a chicken anti-MDV antiserum and visualized by an Alexa 
488 conjugated anti-chicken antibody.  
Statistical analysis. Significant differences in means of tumor incidences (Fig. 
5.5F and H; Fig. 5.6F) and LCL reactivation assays (Fig. 5.11A-C) were determined 
using Student's t test. 
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Summary and Conclusions 
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5.1. VZV P-Oka BAC – generation of a novel tool for VZV research 
Generation of recombinant varicella-zoster viruses (VZV) harboring targeted 
mutations has been one of the major challenges in VZV research. Mutagenesis 
approaches using homologuous recombination in mammalian cells is very inefficient 
and requires plaque purification, which is extremely difficult due to the slow 
replication and highly cell-associated nature of VZV. In Chapter 2 I describe the 
establishment of a full-length bacterial artificial chromosome (BAC) system for strain 
P-Oka strain based on previously established overlapping cosmid clones (1). The BAC 
system (pP-Oka) allowed efficient generation of VZV mutants in E.coli and is now 
widely used by VZV researchers. Transfection of pP-Oka in human melanoma cells 
(MeWo) resulted in the reconstitution of the virus. Replication of BAC- derived virus 
was indistinguishable from wild type P-Oka. Since most applications, such as vaccine 
development, require the removal of foreign bacterial sequences that facilitate 
replication in E.coli (mini-F sequence), we developed a strategy that accomplished the 
elimination of all foreign nucleotides. Hereby, an inversely oriented sequence 
duplication between the positive selection marker (antibiotic resistance gene) and the 
bacterial replicon allowed the removal of the mini-F sequences in mammalian cells, 
while the sequences are maintained in E. coli through antibiotic selection.  
In addition, we previously established a two-step Red-mediated mutagenesis 
technique which allowed a highly efficient and reliable modification of the newly 
established VZV BAC (13). Using these two newly established tools, we investigated 
the role of the major tegument protein encoded by ORF9, a homologue of herpes 
simplex virus 1 (HSV-1) UL49 (VP22) in VZV replication. We mutated the ORF9 
start codon in pP-Oka, which abrogated ORF9 expression, and generated revertant 
viruses in which the start codon was restored. In the absence of the ORF9 gene 
product, virus replication was severely impaired, while wild type and revertant viruses 
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had comparable growth kinetics. Delivery of ORF9 in trans via baculovirus-mediated 
gene transfer partially restored virus replication of ORF9-deficient viruses, confirming 
that the growth defect is attributed to ORF9 gene function.  
Our data clearly demonstrates that ORF9 gene function is essential for VZV 
replication and is in agreement with previous reports on the ORF9 homologue in 
Marek’s disease virus (MDV) UL49 that is crucial for MDV replication in vitro. In 
contrast to VZV and MDV that are highly cell-associated in vitro and in vivo, the 
products of the ORF9 homologues in other alphaherpesviruses that produce 
extracellular, cell-free virus, such as HSV-1 and bovine herpesvirus 1 (BHV-1), are 
not essential in vitro (5, 9, 12). Intriguingly, cell-to-cell spread is significantly reduced 
in BHV-1 (8), suggesting an important role of the ORF9 protein and at least some of 
its homologues in cell-to-cell spread. Recent reports also showed that HSV-1 pUL49 
is required for efficient viral spread in vivo, underlining the importance of this group 
of tegument proteins in herpesvirus replication and pathogenesis (4).  
 
5.2. ORFS/L – implications on UL inversions 
 In addition to that, we used the pP-Oka system to investigate the role of 
ORFS/L (ORF0), which is one of the VZV genes with no known function and no 
direct orthologue in other alphaherpesviruses (7). ORFS/L is located at the extreme 
terminus of UL, directly adjacent to the a-like sequences, which are known to be 
involved in cleavage and packaging of viral DNA. In Chapter 2, we demonstrate that 
the ORFS/L protein localizes to the Golgi network in infected and transfected cells, 
suggesting that it is a functional orthologue of HSV-2 UL56, which has the identical 
subcellular localization and was previously suggested to be the UL56 homologue due 
to its close proximity to ORF3, the homologue of UL55. In addition, we could prove 
that the ORFS/L gene product is important for efficient VZV replication in vitro. We 
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also identified a 5′ region of ORFS/L that is essential for replication and plays a role in 
cleavage and packaging of viral DNA, previously suggested by Davison and 
colleagues (2). Since this essential region has no homology to the opposite end of UL, 
it could provide an explanation for the almost exclusive packaging in VZV virions of 
two viral DNA isomers with an invariable UL orientation.   
 
5.3. vTR – functions of the virally encoded telomerase RNA that are independent 
of the telomerase activity  
Marek’s disease virus (MDV), a highly oncogenic alphaherpesvirus, is 
genetically closely related to VZV discussed in Chapter 2 and 3. Early stages of MDV 
infection resembles primary VZV infection with characteristic skin lesions known as 
chicken pox, however, late stages of infection, specifically latency, are quite distinct 
(11). While VZV establishes latency in long lived neuronal cells and remains 
quiescent until a reactivation event occurs, MDV mainly targets B and CD4+ T-cells, 
which have generally a limited life span. Therefore, MDV evolved several 
mechanisms that promote the survival of CD4+ T cells, likely with a Treg phenotype, 
and allow the maintenance of its genetic information in latently infected cells. In 
Chapter 4 and 5 we shed light on two major factors, viral telomerase RNA (vTR) and 
the viral telomeric repeats, involved in establishment of and reactivation from latency 
as well as tumorigenesis.  
  One factor that significantly contributes to MDV-induced lymphomagenesis is 
vTR, a homologue of host telomerase RNA (TR) (14). In the telomerase complex, 
vTR as well as cellular TR interacts with the catalytic subunit, telomerase reverse 
transcriptase (TERT), and provides the template for the maintenance of telomeres. 
Hereby, interaction of the main components vTR and TERT, which are sufficient for 
telomerase activity, is an essential prerequisite for telomerase activity. As recent 
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studies have suggested that TRs possess telomerase-independent functions, we 
investigated whether the tumor-promoting capacity of vTR is dependent on formation 
of a functional telomerase complex. In Chapter 4 we demonstrate that vTR, the MDV-
encoded telomerase RNA, serves two distinct functions in MDV-induced tumor 
formation. The first is dependent on increased telomerase activity, which is crucial for 
rapid onset of lymphoma formation in infected animals. vTR becomes part of the 
telomerase complex and contributes to the survival of rapidly dividing transformed 
cells. The second function of vTR is independent of telomerase action and is crucial 
for tumor formation and metastasis. This latter function is likely a consequence of 
vTR-mediated gene regulation that is at least in part controlled by interaction of vTR 
with RPL22, a cellular factor involved in T-cell development and virus-induced 
transformation. Taken together, our study demonstrates that telomerase RNA encoded 
by a herpesvirus is directly involved in tumor formation in vivo, in a fashion that is 
largely independent of its function within an active telomerase complex. 
 
5.4. Telomeric repeats – means of entry into and exit out of host chromosomes 
Herpesvirus integration into the host chromosome, as identified for several 
lymphotropic herpesviruses, including Epstein Barr virus (EBV), human herpesvirus 6 
(HHV-6) and MDV, was long thought to be an unintended consequence of viral 
replication (3, 6, 10). In Chapter 5, we identified a directed integration mechanism, 
which ensures faithful virus genome maintenance in host cells during cell division and 
also allows efficient mobilization of dormant viral genomes using MDV as a natural 
virus-host model.  
We demonstrated that directed integration into the host genome is facilitated by 
herpesvirus telomeric repeats, which are present in several herpesviruses including 
HHV-6 and MDV. Our results, therefore, provide the first conclusive evidence that 
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herpesvirus telomeric repeats not only mediate chromosomal integration but that these 
repeat structures are crucial for efficient tumor formation and reactivation of latent 
virus from the quiescent state of infection. In the absence of viral telomeric repeats, 
herpesvirus integration is severely impaired and occurs at random, single sites within 
chromosomes. In this latter case, MDV genomes are integrated as concatemers. Our 
observation that integration occurs even in the absence of telomere-mediated 
integration suggests that herpesvirus integration into the host genome is not simply a 
consequence of virus replication, but rather is a critical prerequisite for transformation 
and tumorigenesis as well as for reactivation and spread to new susceptible hosts. 
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